b e h r n g e r n g e l h e n n u l r e p r value innovationf n ci l h gh l ig h ts um ar r ep r amounts millions eur unless otherwise indicated change net sales region americas europe asia australia africa aaa summary report business human pharma animal health biopharmaceutical contract manufacturing discontinued operations research development expenses personnel expenses average number employees operating income operating income net sales group profit net sales group equity investments tangible assets depreciation tangible assets top products human pharma top products animal health net sales million eur change net sales million eur change jardiance nexgard ofev frontline spiriva heartgard trajenta jentadueto ingelvac circoflex flexcombo v e r v e w core leitbild group management report consolidated financial statements product portfolio c n e n core leitbild shareholders perspective key aspects corporate bodies group management report information group report economic position report opportunities risks report expected developments consolidated financial statements overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report product portfolio human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases animal health livestock swine livestock cattleruminants livestock poultry veterinary public health vph companion animals horse companion animals pets company making new better medicines humans animals heart mission create breakthrough therapies change lives independent familyowned boehringer ingelheim freedom pursue longterm vision looking ahead identify health challenges future targeting areas need good worldleading researchdriven biopharmaceutical com pany almost employees create value innovation daily three business areas human pharma animal health biopharmaceutical contract manufacturing boehringer ingelheim achieved net sales billion euros significant investment almost billion euros rd drives innovation enabling next generation medicines save lives improve quality life realize scientific opportunities embracing power partnership diversity experts across lifescience community working together accelerate delivery next medical breakthrough transform lives patients generations come boehringer ingelheim annual report shareholders perspective shareholders perspective go history year covid pandemic cost two million people lives destroyed livelihoods put society severe test light global challenge pharmaceutical industry expanded research covid unprecedented pace despite comprehensive diverse measures protect life health means pharmacy used combat end pandemic recently would taken ten years identification virus approval vaccine fact vaccines therapies developed made marketready within months made possible close cooperation pharmaceutical companies academia public author ities policymakers responsible creating conditions make innovations possible importance innovationfriendly environment society whole never clearer pandemic company vision creating value innovation affirm commitment excellence science applies fight covid also diseases effective treatment options available yet continue able pursue objectives future want remain makes boehringer ingelheim unique independent economically strong familyowned company global importance would like express special appreciation employees often difficult personal professional environment protected supported one another showing extraordinary commitment great solidarity thus maintaining global supply medicines humans animals desperately need even lockdowns employees continued research develop new therapies least combat covid would like thank outstanding commitment igned christian boehringer chairman shareholders committeethe board managing directors michel pairet carinne brouillonthe board managing directors hubertus von baumbach michael schmelmer jean scheftsik de szolnok photo taken february boehringer ingelheim annual report year shaped sarscov pandemic also boehringer ingelheim researchdriven biopharmaceutical company involved research development therapies beginning national level german center infection research well global alliance companies institutions including bill melinda gates foundation us national institute allergy infectious diseases research center also provided financial assistance donated protective equipment medicines part global support program help counter pandemic times protecting around employees forefront every decision made patient care highest priority boehringer ingelheim high level engagement employees allowed us sustain production logistics throughout despite strained supply chains thus continue supply people depend required medicines thanks outstanding performance department within less week users able perform tasks outside corporate network home every day colleagues continued needed directly site example production facilities laboratories also infrastructure business operations site security efficient infrastructure flexibility staff form basis prerequisite resilience entire organization attained remarkable achievements past year thanks everyones efforts able grow three business areas invested ever researching future therapies one important area research oncology developing active substances directly attack cancer cells also specifically activate human immune system pioneers scientific understanding inflammatory fibrotic diseases skin intestinal lung tissue among things well diseases central nervous system metabolic diseases liver disease nash nonalcoholic steatohepatitis key aspects launch amr action fund joined forces companies ensure infections multiresistant bacteria continue treated effectively new antibiotics future antibiotic resistance least covid show us closely human animal health linked commonality heart strategy particularly animal health focus synergies research external partnerships complement market activities example cooperation chinabased new ruipeng group pet healthcare research pipeline patient information substantial part corporate activities relies various types collaboration complement inhouse strengths specific external skill sets use quantum computers pharmaceutical drug development basic research first pharmaceutical company engage activity entered partnership google quantum ai beginning progress made group past year result covid rather achievement despite challenges associated virus would like extend special thanks employees worldwide made possible high level personal commitment every one us played part ensuring boehringer ingelheim continued make contribution improving lives patients signed signed signed hubertus vo n baumbach carinne brouillon michel pairet signe signe jean scheftsik de szolnok michael schmelmer corporate bodies shareholders committee board managing directors christian boehringer hubertus von baumbach chairman shareholders committee chairman board managing directors christoph boehringer carinne knochebrouillon member board managing directors erich von baumbach human pharma isabel boehringer dr michel pairet member board managing directors dr mathias boehringer innovation prof dr dr andreas barner jean scheftsik de szolnok member board managing directors animal health advisory board michael schmelmer member board managing directors dr nikolaus von bomhard finance group functions chairman advisory board chairman supervisory board mnchener rckversicherungsgesellschaft ag dr hagen duenbostel chief executive officer kws se dr andreas kreimeyer former member board executive directors research executive director basf se dr frank mastiaux chief executive officer ceo enbw energie badenwrttemberg ag jan rinnert chairman board managing directors ceo heraeus holding gmbhpage g r u p n g e e n r e p r information group groups business model research development production employee reporting sustainable development report economic position macroeconomic environment earnings position development businesses financial position net assets position report opportunities risks opportunities risk management individual risks overall statement risk situation report expected developments troper tnemeganam puorg boehringer ingelheim annual report group management report information group groups business model boehringer ingelheim stood innovation years group among worlds leading companies sector founded familyowned company headquarters ingelheim rhein today one germanys researchintensive companies activities focus human animal patients boehringer ingelheims strategic anchor goal achieving medical breakthroughs areas need greatest human pharma animal health biopharmaceutical contract manufacturing businesses company employees worldwide research development rd production commercialization products administration human pharma business mainstay boehringer ingelheims activities accounts share overall sales business area underpinned innovative portfolio many cases companys products standard treatments medicine research focuses cardiovascu lar metabolic diseases oncology respiratory diseases immunology diseases central nerv ous system cns retinal health jardiance jardiance medicine treatment type diabetes also reduces risk cardiovascular strongest diseases type diabetics preexisting cardiovascular conditions groups biggest sell revenue contributor ing human pharma product second consecutive year ofev used treatment rare respiratory disease idiopathic pulmonary fibrosis ipf increasingly also indi cation systemic sclerosis interstitial lung disease sscild registered especially strong growth unmesta tszearllsees n abchy g besuchsifntene sins group million eur biopharmaceutical contract manufacturing sales million eur million eur animal health human pharma million eur million eur group management report net sales region million eur europe asia australia africa aaa americas three products also played significant role boehringer ingelheims success spiriva used treatment chronic obstructive pulmonary disease copd well asthma trajenta used treatment type diabetes pradaxa used prevent strokes patients atrial fibrillation prevention treatment thromboembolic disorders animal health business boehringer ingelheim one biggest providers veterinary vac cines medicines boehringer ingelheim market leader germany global level second largest provider area animal health portfolio includes products pets horses well livestock swine ruminants poultry companys core brands n exgard followed frontline heartgard foundations success pets segment swine segment established swine vaccine ingelvac circoflex used treat porcine circovirus type important component companys product portfolio boehringer ingelheims biopharmaceutical activities comprise manufacture human pharmaceutical products actilyse metalyse praxbind also one worlds leading providers process development commercial production biopharmaceuticals thirdparty industrial customers sales mainly comprise discontinued operations financial year boehringer ingelheim achieved majority sales americas europe regions asiaaustraliaafrica aaa region includes countries china strategic significance groups future development making sales laicnanif detadilosnoc stnemetats boehringer ingelheim annual report research development line mission statement boehringer ingelheims goal research develop innovative medicines therapies treatment diseases yet satisfactory treat ments available major emphasis development medicines well new approaches therapies prevent detect treat chronic diseases driven desire make difference patients aim make relevant contribution areas need treatment high human pharmaceuticals segment well field animal health global research network countries major facilities germany biberach ingelheim rhein usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon well china shanghai boehringer ingelheim continues explore opportunities expanding renewing existing product portfolio organic growth thereby rely longestablished relationships academic institutions biotech companies public research institutions scientific area collaborate projects academic institutions spanning three continents rd expenses also expand research portfolio targeted fashion supplementary cooperation increased license agreements key component boehringer ingelheims innovation strategy supplement net sales broadbased rd portfolio partnerships companys research activities highly productive competitive human pharma aiming source least new molecules pipeline acquisitions third parties high scientific standards business development relationships forged time early investments made boehringer ingelheim venture fund proven strong advantage groups research development expenses increased considerably recent years past three years growth even outpaced revenue trend group management report research development expenses million eur net sales human pharma expenses million eur human pharma net sales animal health expenses million eur animal health net sales average number employees investments tangible assets million eur without investments infrastructure boehringer ingelheim acquired belgian veterinary biotech company global stem cell tech research network nology nv dedicated research development production evidencebased regen expanded erative medicines already used treat orthopedic diseases animals human pharma business boehringer ingelheim reinforced position area immunoncology therapies acquiring shares canadian company northern biologics inc subsequently renamed bi io canada inc group also expanded portfolio collaborations partnerships past year boehringer ingelheim entered new partnerships include relationships us firm mirati therapeutics inc investigating use pankras inhibitors fight tumors swiss company numab therapeutics ag goal developing commercializing multispecific antibody therapies potential treatment lung gastrointestinal cancers well geographic atrophy another new partner cdrlife inc likewise headquar tered switzerland also focuses latter indication hand boehringer ingelheims new cooperation british company enara bio ltd aims discover novel antigens future cancer immunotherapies addition click therapeutics inc usa pursuing inno vative approach development commercialization digital therapeutic treatment schizophrenia shortly end year boehringer ingelheim signed agreement acquire nbetherapeutics ag area oncology transaction completed january additionally negotiated acquisition contract manufacturer labor dr merk kollegen gmbh completion transaction subject usual closing conditions expected take place course financial year laicnanif detadilosnoc stnemetats boehringer ingelheim annual report rd sites animal health ah human pharma hp americas europe asiaoceania brazil belgium australia paulnia ah evergem ah sydney ah mexico germany china guadalajaratateposco ah biberach hp shanghai ah ingelheim rhein ah taizhou ah usa katharinenhofrohrdorf ah ames iowa ah japan athenscolbert georgia ah france kobe hp duluth georgia ah lyon ah tokyo ah fulton missouri ah saintvulbas ah gainesville georgia ah new zealand north brunswick new jersey ah netherlands auckland ah ridgefield connecticut hp lelystad ah st joseph missouri ah austria innsbruck hp vienna hp switzerland geneva hp financial year bi x boehringer ingelheims digital laboratory opened second facility total employees presence shanghai well ingelheim rhein past year bi x development teams transferred several innovative digital products com panys businesses instance adam helps researchers early pharmaceutical research identify relevant candidates order address target molecule bi x also added portfolio services companywide scouting service helps identify evaluate potential partners field digital technologies group management report since boehringer ingelheim venture fund driven innovation strategic invest ments earlystage science technology venture fund invests biotech startup compa nies innovative concepts technologies potential provide groundbreaking therapeutic platforms venture fund also founds companies identifies promising research projects universities academic institutions research institute molecular pathology imp vienna biomedical research institute primarily funded boehringer ingelheim scientists approximately countries imp conducts research molecular cellular mechanisms form basis complex biological life processes well human diseases imp one worlds leading institutions kind late group leaders received least one pres tigious grants awarded european research council erc success rate erc applications period imp ranked third among european research institutes universities five six senior scientists elected full members european molecular biology organization embo boehringer ingelheims rd activities preclinical well clinical research development basis companys sustainable success innovative capability played key role groups positive business development past years inhouse rd supplemented external cooperation partnerships also continue top priority future financial year employed average people rd facilities total around billion eur invested research development new medicines level corresponds around groups net sales laicnanif detadilosnoc stnemetats boehringer ingelheim annual report human pharma new became particularly apparent trusting collaboration modern science decisive active substances goal transform lives patients areas significant unmet medical need human human pharma portfolio pharma rd focused areas cardiovascular metabolic diseases oncology respiratory diseases immunology diseases central nervous system cns retinal health end human pharma research portfolio included new substances whose development registration work around clinical preclinical projects development pipeline end phase cardiometabolic diseases hemodynamic modulator phase hemodynamic modulator phase anorectic phase transcient receptor potential channel inhibitor phase bi phase ii glpgcgr agonist obesity empagliflozin new indication phase iii sglt inhibitor ckd empagliflozin new indication phase iii sglt inhibitor chf oncology pd antibody phase mrna vaccine phase vegfang antibody phase bet inhibitor phase lrp inhibitor phase mdmp antagonist phase sirp antagonist phase soskras inhibitor phase mek inhibitor phase kisima cancer vaccine phase trailrcdh antibody phase dllcd bispecific antibody phase sting agonist phase xentuzumab bi phase ii igf antibody mbc group management report development pipeline end phase respiratory diseases cysteine protease inhibitor phase leukocyte protease inhibitor phase bi phase ii antifibrotic ipf immunology epithelial barrier stress modulator phase receptor serine threonine kinase phase spesolimab bi phase ii ilr antibody gpp spesolimab bi phase ii ilr antibody ppp spesolimab bi phase ii ilr antibody atd spesolimab bi phase ii ilr antibody cd spesolimab bi phase ii ror antibody psoriasis central nervous system diseases phosphodiesterase inhibitor phase nmda receptor modulator phase osoresnontrine bi phase ii pde inhibitor fep osoresnontrine bi phase ii pde inhibitor rex bi phase ii glyt inhibitor cias bi phase ii trpc inhibitor mdd bi phase ii trpc inhibitor bopd laicnanif detadilosnoc stnemetats boehringer ingelheim annual report development pipeline end phase retinal health neuronal damage modulator phase vegfang antibody phase ischemia modulator phase covid sarscov neutralizing antibody phase bi phase ii trpc inhibitor cov iards indication abbreviations atd atopic dermatitis cov mdd major depressive disorder iards covid induced acute bopd borderline personality disorder respiratory distress syndrome mi myocardial infarction cd crohn 's disease fep first episode psychosis ppp palmoplantar pustulosis chf congestive heart failure gpp generalized pustular psoriasis rex reduction relapse cias c ognitive impairment hf heart failure schizophrenia schizophrenia ipf idiopathis pulmonary fibrosis ckd chronic kidney disease mbc metastatic breast cancer partnered projects acquired assets study complete submissions ongoing progress prevention hf post mi study terminated end february key pipeline advances dec dec interconnected cardiorenalmetabolic conditions affecting heart kidneys metabolic sys tem leading cause mortality worldwide account million deaths annually building expertise developing innovative treatments range cardiovascular met abolic conditions rd strategy cardiometabolic diseases takes holistic view thera peutic needs people affected multiple related cardiovascular metabolic conditions explore impact empagliflozin jardiance major clinical cardiovascular renal comes spectrum cardiorenalmetabolic conditions boehringer ingelheim lilly alli ance developed empower program adults enrolled worldwide one broadest comprehensive clinical programs sglt inhibitor date reported positive results emperorreduced phase iii trial adults heart failure reduced ejection fraction without diabetes addition announced initiation empactmi collaboration duke clinical research institute trial sglt inhibitor class investigate prevention heart failure acute myocardial infarction patients without diabetes convinced use highly innovative approaches make difference transforming lives cancer patients focus lung cancer cancers gastrointestinal tract collaborating oncology community deliver scientific breakthroughs firstinclass treatments help win fight cancer commitment resulted treatments lung cancer giotrif vargatef rich pipeline advanced compounds clinical development taking cancer focusing scientific approaches cancer celldirected agents immunooncology therapies well smart combination good competitive position projects partners university texas md ander son cancer center mirati therapeutics numab therapeutics oxford biotherapeutics others also achieved progress approaches combination group management report scientific research new therapeutic concepts people respiratory diseases another focus boehringer ingelheim example following decade research break pulmonary fibrosis therapy achieved since ofev nintedanib treat ment option idiopathic pulmonary fibrosis ipf slow decline lung function countries people living systemic sclerosis associated interstitial lung disease sscild chronic fibrosing interstitial lung diseases progressive phenotype pfilds approved treatment option existed countries far first therapy ofev approved countries treatment sscild countries treatment pfilds marks turning point treatment wide range rare forms pulmonary fibrosis still therapeutic need inpedild study boehringer ingelheim investigating dosing safety profile nintedanib children adolescents yet projects completed successfully boehringer ingelheim bridge biotherapeu tics mutually agreed termination collaboration autotaxin inhibitor fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis ipf boehringer ingelheim dedicated discovering developing firstoftheirkind therapies help treat serious inflammatory diseases greatly impact patients lives emotionally physically deep understanding molecular pathways boehringer ingelheim pioneering scientific breakthroughs target repair prevent inflammatory diseases skin gut joints spesolimab advanced investigational compound boehringer ingelheims immu nology pipeline boehringer ingelheim aims give people serious inflammatory diseases chance lead selfdetermined fulfilled life important neuropsychiatric diseases schizophrenia depression continue center boehringer ingelheims research central nervous system diseases boehringer ingelheim currently broadening development activities boehringer ingelheim started two phase ii trials treatments borderline personality disorder major depressive disorder positive results phase ii clinical trial patients cognitive impairment associated schizophrenia furthermore broadened innovative activities schizophrenia inlicensing digital therapy click therapeutics retinal diseases agerelated macular degeneration leading cause legal blindness developed world although current therapies retinal diseases exist limited effectiveness real world significant unmet treatment needs still exist boehringer ingelheim therefore expanded global research development activities retinal dis eases first assets already clinical development work scientists complemented collaborations academic patient organizations alongside partnerships biotech com panies new partnerships announced development antiinflamma tory aoc inhibitor treatment patients moderate severe nonproliferative diabetic retinopathy npdr pharmaxis discontinued laicnanif detadilosnoc stnemetats boehringer ingelheim annual report researchdriven biopharmaceutical company utilize different areas expertise find medical treatments covid initially look portfolio identify compounds may potential manage symptoms tissue damage related sarscov infec tion directly tackle virus worked together cologne university hospital ukk university marburg umr german center infection research dzif identified sarscov neutralizing antibody entered phase clinical studies sponsored ukk addi tion involved different consortia care corona accelerated rd europe con sortium project innovative medicines initiative imi european union covid therapeutics accelerator cta bill melinda gates foundation bmgf aim identify next generation neutralizing antibodies novel small molecule inhibitors viral proteins host factors responsible replication sarscov provided compounds historical small molecule library including legacy hiv hcv assets previous virology projects well molecules selected computational screening proteases sarscov screening hope provide starting points new compound optimization campaigns conducted part collaborative consortium efforts convinced novel platform approaches enable us discover new medicines across therapeutic approaches disease boundaries tackling common diseasecausing mechanisms strategy study immune modulations context oncology inflammation fibrotic diseases across organs lung liver eye kidney following table shows relevant changes current clinical studies phase iii studies people covid group management report clinical trial phase changes empalinamet xr fixeddose combination tablet phase iii approved usa empagliflozin linagliptin metformin completed extended release xr treatment adults type diabetes emperorreduced nct phase iii phase iii study completed primary endpoint met randomized doubleblind trial investigating published new england journal medicine daily empagliflozin compared placebo empagliflozin significantly reduced com adults heart failure reduced ejection bined relative risk cardiovascular death fraction without diabetes hospitalization heart failure receiving current standard care adults without diabetes heart failure reduced ejection fraction empagliflozin also significantly reduced relative risk first recurrent hospitali zations heart failure signi ficantly slowed kidney function decline emperorpreserved nct phase iii phase iii ongoing randomized doubleblind trial investigating daily empagliflozin compared placebo adults chronic heart failure preserved ejection fraction without diabetes receiving current standard care inbuild nct double blind phase iii approved countries randomized placebocontrolled trial evaluating completed including usa eu efficacy safety nintedanib weeks patients progressive fibrosing inter stitial lung disease pfild senscis nct double blind phase iii approved eu april randomized placebocontrolled trial evaluating completed approved countries efficacy safety oral nintedanib treatment least weeks patients systemic sclerosisassociated interstitial lung disease inpedild nct double blind phase iii ongoing randomized placebocontrolled trial evaluating dosing safety profile nintedanib children adolescents years old clinically significant fibrosing interstitial lung disease bi nct phase ii ongoing trpc inhibitor ards covid study inhibitor trpc inhibitor transient receptor potential cation channel investigate whether selective inhibitor may reduce need ventilator support improve patient recovery rates ultimately save lives patients hospitalized covid bi nct nct phase iiia ongoing studies investigate efficacy safety neutralizing antibody development new therapeutic prophylactic treatment option covid study terminated end february laicnanif detadilosnoc stnemetats boehringer ingelheim annual report animal health research development activities area animal health boehringer ingelheim concen trates research development supply pioneering treatments preventive therapies areas medical need currently unmet greatest impact includes innovative vaccines antiparasitics protection livestock pets well phar maceutical products treatment chronic diseases rd unit animal health business renamed animal health global innovation given new organizational structure based disease systemcentered research development approach enables us effectively examine diseases larger populations crossspecies basis step cooperation human pharma colleagues external partners bring market pioneering innovations treatment well preven tive veterinary therapies defined six regional innovation centers strategically important regions order boost approach encourage cooperation three situated united states two europe francenetherlands germany one china centers consist local clusters spe cific areas competence enable us cooperate within disciplines multidisciplinary basis implement strategy local level following concentration vaccine research development activities france usa german facility hanover discontin ued activities end external partnerships also play key role possible realize innovations broad scale new areas internal efforts alone addition internal research development activities evaluate external projects products appropriate seek pursue joint development routes partners july acquired belgian veterinary biotech company global stem cell technology nv specializes research development manufacturing evidencebased regenerative medicines stemcell therapies treatment orthopedic immunological animal diseases acquisition enable us strengthen existing capacities equine segment also produce groundbreaking innovations species september joined forces fraunhofer institute molecular biology applied ecology ime order develop next generation safe effective sustainable antiparasitics initiated clinical studies worldwide awarded prod uct authorizations including approval eu usa innovative awardwinning aservoequihaler alleviation severe equine asthma obtaining approvals new products new areas application expanding geographic scope sales activities existing products additional important aspects research development activities help us create value innovation group management report production facilities animal health ah human pharma hp biopharmaceutical contract manufacturing bio americas europe italy asia oceania brazil belgium fornovo hp china itapecerica hp evergem ah noventa ah nanchang ah paulnia ah shanghai hp bio denmark netherlands taizhou ah mexico kalundborg ah lelystad ah guadalajara ah indonesia xochimilco hp germany austria bogor hp biberach bio vienna bio puerto rico dortmund hp japan barceloneta ah ingelheim rhein hp spain yamagata hp sant cugat hp usa france new zealand athens georgia ah lyon ah united kingdom auckland ah fremont california bio toulouse ah pirbright ah gainesville georgia ah st joseph missouri ah greece worthington minnesota ah koropi hp production human pharma human pharma business globally acting production division responsible reliable supply topquality medicines patients ongoing development companys internal pro duction facilities strategic cooperation external manufacturers established mod ern flexible market supply network encompasses entire value chain suppliers start ing materials worldwide logistics distribution finished pharmaceutical products boehringer ingelheims production facilities concentrate products strategically important company well stateoftheart cases unique manufacturing technologies time partnerships external manufacturers add specialist technologies produc tion network available inhouse also expand production capacity standard technologies products high capacity requirements already far advanced terms life cycle laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial year global network included boehringer ingelheims plants nine countries group four biopharmaceuticals facilities also two facilities manufac ture pharmaceutical active substances one produces medical devices eight manu facture finished pharmaceutical products even past year unusual due covidrelated logistical challenges boehringer ingelheim able ensure steady supply medicines patients possible due fact key manufacturing steps technolo gies established multiple facilities inventory reserve concept implemented every step supply chain continuing digitalization production network overall supply chain plays key role ongoing development measures ensure security supply delivery capacity patient care top priorities boehringer ingelheim company consist ently makes important investments development transformation production capacities chemical pharmaceutical network ingelheim rhein headquarters boehringer ingelheim made significant progress line planning implementation key invest ment flexible plant industrialization newly developed medicines initial market supply initiated expansion production technologies capacities pharmaceutical active substances fornovo italy facility finished pharmaceutical products koropi greece yamagata japan facilities ensure supply antidiabetic products particularly jardiance well pipeline products continuing expansion biopharmaceuticals vienna facility serves expand capacities network newly developed products covers increased demand actilyse products ongoing implementation groups supply chain strategy optimizes management value chain supplier customer endtoend use modern digital automated processes technologies enables high level transparency efficient management global production network supply chain animal health animal health products manufactured worldwide sale network production facilities twelve countries addition companys facilities around contract animal health manufacturers turned products boehringer ingelheim companys product portfolio com production facilities prises vaccines pharmaceutical products nutraceuticals traditional products supple twelve countries mented diagnostic products well monitoring solutions including digital applications used livestock monitoring link livestock owners veterinarians optimization companys production network continues remains priority goal ensuring robust efficient supply products boehringer ingelheim invested capacity expansion strongest revenue contributor nexgard barceloneta puerto rico facility expansion small animal vaccine produc tion companys facility athens georgia usa expansion vaccine capacity lyon france st joseph missouri usa capacity expansion footandmouth disease vaccines jonage france also invested development innovative technologies manufacture products group management report biopharmaceutical contract manufacturing boehringer ingelheim pursues biopharmaceutical activities facilities biberach germany one leading vienna austria fremont california usa shanghai china comprise manufacture providers ownbrand marketable products actilyse metalyse praxbind biopharma industrial customers ceuticals clinical testing bi also one worlds leading companies process development launch preparation commercial production biopharmaceuticals thirdparty industrial customers twelve top pharmaceutical companies innovative biotech firms clients biopharmaceutical contract manufacturing business boehringer ingelheim covers entire biopharmaceutical value chain development production cell mammalian cells well microorganisms production process manufacture active substance finished pharmaceutical product product launch global market supply capacity utilization networks industrialscale production facilities remained high level increased market demand actilyse biberach facility addition two new customer products monoclonal antibodies cancer therapy approved biopharma ceutical contract manufacturing business process validation precondition approval successfully completed another two products facility fremont california usa succeeded gaining authorization produce customers pharmaceutical product thus possible meet rising product demand within network biberach fremont customer product vienna facility also approved international authorities despite challenging external conditions associated covid cell culture plants biberach shanghai fremont microbial production vienna continued reliably manufacture deliver biopharmaceuticals patients worldwide without incurring interruptions almost completed process expanding capacities vienna facility initial test runs successfully completed end year commissioning qualification process well advanced whereby measures ensure employees safety context covid made work even complex early new energy center already operating full capacity new cell culture production building granted official authorization operate additional microbial expansion project production recombinant vaccine high level demand expected complete commissioning qualification process time two projects key strategic significance view growing global impor tance biotechnologically produced active substances shanghai china hospital products products commercial market manufactured local export markets line planning first biopharmaceutical product win approval chinas new contract manufacturing regulatory requirements first commercial product delivered customer approval launch final milestones pilot project boehringer ingelheim chinese regulatory authorities new rules governing coop eration marketing authorization holder customer contract manufacturer evaluated successfully applied boehringer ingelheims facility shanghai thus recognized contract manufacturer cmo chinese authorities successfully completed expansion oasis production facility shanghai second l bioreactor commercial produc tion began early october laicnanif detadilosnoc stnemetats boehringer ingelheim annual report employee reporting number employees boehringer ingelheim employed people average worldwide represents continues increase increase previous year number staff increased every region average number employees region americas europe asiaaustraliaafrica aaa major success factor positive growth group engaged motivated staff place considerable emphasis actively developing supporting employees order best prepared challenges ahead emphasize acquisition technical expertise also promote social skills part comprehensive qualification system core aspects mission statement particularly relevant success company relies strength employees aim improve human animal health feel sense responsibility toward communities operate part global support program fight covid enabled employees take days fully paid leave period april december could volunteer external organizations offer employees opportunity way help meet urgent need volunteers medical background impact covid pan demic work private life demanded great deal employees employees worldwide given opportunity take paid vacation december january inclusive investing flexible infrastructure digital technologies even prior pandemic cre ated important prerequisites enable users work seamlessly home time thus able protect employees safeguarding business activities ensuring global supply medicines making progress researching treatment options preestablished central digital tools work flows digital channels also ensured communication medical experts veterinarians pet owners however pandemic raised challenges us also identified opportunities early adapted digital learning formats training concepts apprentices students enrolled dualstudy courses covid conditions established additional training courses help employees work virtual teams document new experiences insights regarding new virtual work methods tools meeting formats business travel well role offices future work concept future provide global framework modern flexible approach work boehringer ingelheim beyond covid group management report boehringer ingelheims success based innovation well presence countries global nature value chain international nature clientele stringent sub stantially varying requirements national regulators demand great flexibility organization whole convinced relationships based trust well mutual openness respect empathy values make us strong competitive diversity thought spirit inclusion relationships one another promote capacity innovation every area business addition competitive salaries boehringer ingelheim offers benefits employees benefits include range company pension plans flexible homebased work options numerous healthrelated benefits significant segment corporate strategy human resources departments scope duties includes promoting wide range opportunities innova tion work helping employees nurture talents develop individuals vocational training always major importance boehringer ingelheim company pro vides many young people career entry opportunities time also tie talented wellqualified workforce young professionals company backdrop demographic change however company vocational training mean passing expertise also emphasize getting know one another enable young professionals experience many aspects company values new recruits began training dualstudy courses unusual circumstances boehringer ingelheim anticipated effects pandemic developed concept enabled people get know one another person subject strict safety concepts plants also providing large number new digital learning formats boehringer ingelheims german facilities young people started careers different scientific technical commercial fields training dualstudy courses average young people worldwide enrolled vocational training program one companys aims strengthen appeal boehringer ingelheim employer current future employees boehringer ingelheim recognition top employer auditors international independent top employers institute addition germany boehringer ingelheim also received award argentina austria brazil china colombia indonesia italy malaysia philippines poland romania russia singapore spain south korea thailand vietnam sustainable development sustainability firmly anchored corporate philosophy since companys founding familyowned business boehringer ingelheim plans generations generations sustainable development efforts leverage unique strengths global human animal health company guided core values empathy respect passion trust well focus leitbild aspire towards healthier world people communities reach full potential aspire positive impact health society planet laicnanif detadilosnoc stnemetats boehringer ingelheim annual report achieve sustainability future generations efforts focus three main areas health focusing good health people animals potential focusing people communities green focusing environment health key initiatives angels optimize stroke care boehringer ingelheim established angels initiative together european stroke organisation eso world stroke organization wso stroke alliance europe safe many national stroke associations companies past year initi ative achieved goal developing network clinics worldwide countries ensure stroke patients treated line defined standards overall doc tors nurses involved lastmile south sahara small farmers africa always access veterinary treatments boehringer ingelheims lastmile initiative seeks tackle problem together bill melinda gates foundation galvmed goal longterm sustained improvement availa bility veterinary medicine creation awareness issue project launched kenya currently expanded include central markets cameroon nigeria mali burkina faso ethiopia also plans include tanzania initiative targets ruminants sheep goats cattle well poultry mission establish longterm partnerships small farming communities promote sustainable economic activities target countries boehringer ingelheim launched mobile app part initiative enables local lastmile teams employees manage daily activities work effectively farmers traders veterinarians app helps precise monitoring activities data collection evaluation impact scope initiative thus helps us better understand challenges improve knowledge smallfarming sector future enable us make informed decisions based reliable data potential key initiatives making health major pillar social commitment making health mmh initiative partnership ashoka since start continuously developed social entrepreneurship move ment within company externally emphasis cocreating sustainable solutions empower local communities startups leveraging boehringer ingelheims employees expertise engagement vulnerable communities mmh helps people living poverty line many different areas daily lives health infrastructure education incomegen erating measures activities various projects aim systemic change mmh supports activities development sustainable business models social entrepreneurs worldwide established broad diverse network local international partners different sectors cocreation bridge social commercial entrepreneurship brings together social entre preneurs nonprofit organizations health care sector boehringer ingelheim employ ees resources group management report networking across traditional visible invisible borders central element successful social movement order identify promote implement innovative solutions farreaching complex challenges health care sector mmh network consists social entrepreneurs area health care boehringer ingelheim ashoka one worlds largest nonprofit organizations together reached approximately million people worldwide mmh initiative promotes employees commitment social entrepreneurship order advance health care projects many different countries working local external partners well colleagues throughout boehringer ingelheim several mmh leadership programs established past years insights india insights kenya rural southern india kenya mmh business accelerator kenya nigeria ghana social intrapreneurship online courses executives residence program provides opportunities collaborate social entrepreneurs mmh network internal competition promoting employees projects mmh leadership programs nurtured staffs social entrepreneurial thinking activi ties contributed significantly local communities also strengthened network ing philosophy partnerships nonprofit organizations social enterprises health care sector large number local projects taken shape employees actively involved improving health means understanding peoples environment everyday challenges offering solutions needed health awareness affordability accessibility health services acceptance play key role mmh active university sector goal helping students lecturers learn social entrepreneurial thinking practical activities development health carerelated projects diversity inclusion boehringer ingelheim convinced employees diverse ideas strengths interests back grounds critical success company see major competitive advantage diver sity employees helps us better fulfill various needs requirements patients around globe also strengthens performance workplace determined create work environment employees granted high level respect irre spective gender nationality ethnic origin religion worldview abilities age sexual orientation identity steadfastly oppose form discrimination part global commitment area participating multiple internal external initiatives intended promote diversity inclusion throughout company support ongoing development networks employees different walks life granted voice includes networks gender roles working world people identify lgbtiq people disabilities outside company active members national international associations pro mote communication exchange knowledge best practices delighted published successfully executed first action plan germany implementation un convention rights persons disabilities thus serve exam ple many companies germany continuing focus prout work conference motto achievingmoretogether sought optimal ways various diversity dimen sions work together benefit one another laicnanif detadilosnoc stnemetats boehringer ingelheim annual report safe health protection safety prerequisite production processes business planning decisionmaking offer employees safe workplace safe zero choice program promotes exchange best practices increases employees level safety awareness well training green key initiatives protection employees environment well sustainable use natural resources promotion environmental awareness major components companys mission statement prime importance boehringer ingelheim groupwide company developed binding standards terms environmental protection health safety work internal guidelines reflect respective countryspecific require ments many cases go far beyond standards prescribed law particular follow international standards guidance documents closely cooperate various associations within boehringer ingelheim environment health safety sustainability ehss department responsible strategic focus launched green future choice program underwent develop ment set new strategic global goals period taking business growth account program optimize green activities facilities business areas worldwide factoring value chain program considers many different environ mental aspects building facilities close nature provide habitats variety plants ani mals encouraging green behavior employees adopting measures avoid water air pol lution using renewable energy reducing waste creating environmentally friendly products well implementing certified systems environmental protection energy management continuously work measures reduce co emissions facilities aim continuously lower greenhouse gas emissions associated global operations purchasing energy renewable sources planning reductions emissions across value chain concentrating sustainability major projects established green capital expenditures fund well internal co pricing method order invest green future promote environmentally friendly solutions group management report using digitalized solutions working implementing globally efficient processes stand ardized software solutions global digitalization projects collection environmental data groupwide green program electronic signature solutions ehs audit systems successfully supported implemented digitalization approach enables us rationalize activities throughout world reduce expenditure without suffering quality per formance losses certification production rd facilities standards iso iso iso serves basis internally externally recognized ehs management systems many bi facilities already achieved solid certification status systematic continuous improvement ehss facilitates compliance legislation reduces licensing fees generates energy savings reduction internal audits positive public profile two exam ples global standards maintained boehringer ingelheim aware need active water management programs access suffi ciently clean water impact social cultural justice ecological sustainability commer cial benefits therefore introducing water management programs facilities prone water risk reducing volume medicines left production wastewater require suppliers production facility xochimilco mexico valid alliance water stewardship aws certification boehringer ingelheim first pharmaceutical company worldwide receive certification according globally recognized standard antimicrobial resistance amr poses increasingly serious threat global public health requires action every level government well businesses society large reason boehringer ingelheim joined amr industry alliance one largest private coalitions estab lished offer sustainable solutions combating antimicrobial resistance boehringer ingelheim supports objectives nagoya protocol concerned aspects biodiversity relevant activities pharmaceutical sector laicnanif detadilosnoc stnemetats boehringer ingelheim annual report report economic position remain memories long time sarscov pandemic caused great deal suffering many people world many experienced considerable economic cutbacks would like extend sympathy thanks due made tre mendous efforts care sick particularly vulnerable people well families lock time pleased researchdriven biopharmaceutical industry able utilize strong global partnerships develop solutions unprecedented pace allows us look confidently future macroeconomic environment world economic output fell around largest decline several decades chiefly due effects covid pandemic second quarter especially consequences antipandemic measures lockdowns curfews resulted dramatic reduction economic output trade volume private investments particularly developed emerging economies extensive public investments cushioned impact immediate economic consequences consumers companies unlike previous crises parts service industry particu larly badly affected social distancing measures ongoing trade tensions usa china united kingdoms brexit negotiations eu placed additional burden international trade investment activities general however overall conditions direct immediate impact strongly cyclical sec tors economy due essential nature products longterm preparation brexit pharmaceutical markets less affected hurdles general predomi nantly influenced performance capability national economies demographic develop ment societies especially longterm basis performance also shaped continuous global improvement access medical care global pharmaceutical market thus grew past financial year unlike many sectors severely affected crisis however growth lower previous year preliminary estimates currently suggest growth least source iqvia due fact especially industrialized nations visits doc tors offices hospitals postponed covid pandemic resulted decline demand products addition social distancing measures resulted delays clinical studies pharmaceutical industry thus affected research activity schedules since core business stable compared sectors pharmaceutical firms able make strong contribution fight covid increasing research development investments sarscov virus group management report continued efforts number countries including core markets reduce rising health care expenditures means regulatory action lower pharmaceutical prices also increasing number initiatives seeking shift burden payment onto patients limit opportunities access innovative medicines include example government imposed industrywide price reductions mandatory reference price systems imports medicines lowercost countries approaches also include mandatory substitution patented med icines generics furthermore protection intellectual property increasing pres sure pharmaceutical strategy europe presented european commission end declared aim sustainably strengthening attractiveness europe research production location improving access medicines therapies important prerequisite achieving objective remains reliable legal framework promotes innovation ensures protection intellectual property critical tendencies aimed weakening incen tive instruments would wrong signal would shift future cuttingedge research investment pharmaceutical innovation regions world impact also supply europe animal health industry focuses pets livestock strong growth path emerging markets particular due population growth improving living standards many people animal health market characterized rising demands animal proteins well increasing popularity pets impact covid pandemic segments varied product sales increased pet segment despite limited physical access veterinary clinics times livestock segment partly experienced drastic decline demand due closures slaughter houses restaurants online channels becoming increasingly important largely made lack physical access covid pandemic general consolidation mergers supplier customer side ongoing leads increased competition future growth animal health business largely driven therapeutic innovation order grow faster market investment innovation area vital therapeutic areas particular company expects able realize synergies human pharma business continuous sustained competitive investment innovation play key role analogous human pharma segment financial year boehringer ingelheim implemented extensive range measures min imize impact covid pandemic employees patients society large protect health workforce another important aspect activities safeguarding produc tion supply medicines patients well veterinary pharmaceuticals pet live stock owners boehringer ingelheim able realize objective thanks broad pro duction supplier network second quarter year company even fulfilled peak wholesaler pharmacy demand generated strategic stockpile purchases environment boehringer ingelheim defended market position thanks dedication workforce capacity innovation particularly strong competitive investment inno vation thus able make major contribution human animal health laicnanif detadilosnoc stnemetats boehringer ingelheim annual report according international monetary fund global economy grow trade policy new us government withdrawal agreement concluded united kingdom eu offer prospect significant upswing successful production distribu tion application covid vaccines also positive effect however according imf also many risks realized could lead weaker growth include lockdowns due uncontrolled spread covid pathogen heightened geopolitical ten sions weatherrelated natural disasters due global presence boehringer ingelheim affected changes foreign exchange rates par ticularly us dollar usd japanese yen jpy increasingly chinese renminbi cny us dollar fluctuated eurusd january low eurusd decem ber following interim high eurjpy may japanese yen ended year low eurjpy december around lower start year chinese renminbi reached high eurcny february interim low eurcny july emerging mar kets currencies also highly volatile significant transactional currency risks hedged suitable currency instruments currency development effect net sales average rate basis eur million eur us dollar japanese yen chinese renminbi earnings position stable competitive earnings position solid financing guarantee boehringer ingelheims inde pendence therefore central activities basis pursue guiding prin ciple value innovation contribute improvements human animal health means innovative therapies despite covid pandemic business performance positive boehringer ingelheim recorded net sales million eur corresponds increase compared billion eur sales previous years million eur exchange rate development foreign exchange markets associated exchange rate effects negative impact sales trend adjusted effects group grew regions contributed growth sales million eur share overall sales americas region remains boehringer ingelheims key sales market americas region sales increased yearover year currencyadjusted sales europe region rose million eur currency adjusted region accounts groups net sales growth driven countries central eastern europe well germany spain united kingdom italy group unable match previous years sales volume asiaaustraliaafrica aaa region also realized strong growth currencyadjusted revenues mil lion eur generated region corresponding share groups total revenues strategically important chinese market provided companys overall sales volume represents currencyadjusted increase yearoveryear among factors market group management report benefited decline incidence african swine fever negatively affected growth net sales region million eur currency change adjusted americas europe asiaaustraliaafrica aaa human pharma business made products available patients growth thanks new approvals additional countries also strengthened established products regions boehringer ingelheim already begun introduce digital customer relations strategies previous years local sales organizations successfully expanded strategies covid restric tions played even important role customer relations activities strategic growth areas animal health business registered positive results however parts livestock segment strongly impacted effects covid measures instance cus tomers sales declined due closure slaughterhouses restaurants key figures million eur change net sales operating income return net sales income taxes income taxes materials ratio taking consideration change inventory improved personnel expenses increased primarily due additional employees hired areas research development medicine biopharmaceutical medicine production strategic significance boehringer ingelheim addition increase average number employees higher personnel expenses reflect effects associated additional vacation days granted employees provide support well performancerelated compensation enables employees share companys success amortization intangible assets depreciation tangible assets increased million eur comparison rise mainly reflected higher valuation adjustments intangible assets animal health human pharma businesses depreciation tangible assets also increased due continuing high volume investment activities increase operating income million eur demonstrates boehringer ingel heim resolutely pursuing longterm goal profitable growth business areas addition positive sales trend business activities lower operating costs yearoveryear also contrib uted improved level operating income return sales thus increased laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial year income taxes rose due particular higher operating income financial income declined overall due reduced income plan assets cover pension similar obligations well lower level income longterm securities partly set holding income influenced oneoff effects income taxes higher previous year reflects favorable course business noteworthy regard provisions german commercial law share holders personal taxes arising group business activities may recognized tax expenses instead taxes presented part withdrawals group equity taking specificity account actual tax ratio markedly higher figure shown profit loss statement despite challenging market conditions business areas boehringer ingelheim registered pos itive performance financial year improved level profitability enabled additional million eur research development investments including race develop therapies treat health group profit effects covid following group profit million eur previous year figure rose million eur million eur development businesses previous year boehringer ingelheims activities divided human pharma animal health biopharmaceutical contract manufacturing businesses net sales businesses million eur currency change adjusted human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations human pharma around total group revenue human pharma main pillar boehringer ingel heims business activities context covid restrictions company effectively expanded scope digital information strategies already established previous years crucial since important scientific symposia activities pharmaceutical repre sentatives greatly limited could take place due contact restrictions human pharma sales amounted million eur equivalent growth currencyadjusted compared previous year positive sales trend resulted primarily increased sales products jardiance family ofev company achieved growth yearoveryear regions despite price pressure particularly established medicines boehringer ingelheim suc cessfully held continues pursue reorganization human pharma product port folio planned included sale nonstrategic products financial year grow ing licensing business particular skyrizi licensed abbvie also contributes positive development human pharma segment group management report previous year jardiance used treat type diabetes companys biggest revenue contributor achieved sales million eur jardiance reporting period represents currencyadjusted increase yearoveryear net sales million eur currency change adjusted jardiance ofev spiriva currencyadjusted trajenta jentadueto growth ofev pradaxa last year ofev boehringer ingelheims secondstrongest revenue contributor first time product used treat idiopathic pulmonary fibrosis increasing extent two addi tional indications sscild pfild ofev generated sales million eur represents currencyadjusted growth significantly exceeded previous years figure spiriva used treatment chronic obstructive pulmonary disease copd thirdstrongest product boehringer ingelheim 's portfolio sales million eur revenue lower previous year million eur expected view products life cycle trajenta jentadueto treatment type diabetes registered slightly lower sales volume million eur sales million eur financial year anticoagulant pradaxa likewise fell marginally short previous years result nonetheless remains one boehringer ingelheims strongest revenue contributors risankizumab medication treatment plaque psoriasis mainly developed boehringer ingelheim successfully marketed globally partner abbvie brand name skyrizi revenues license agreement increased yearoveryear currencyadjusted regard regional distribution revenues human pharma business usa largest market share boehringer ingelheim generated sales million eur corresponds increase compared previous year currency adjusted eucan region europe canada australia new zealand secondbiggest market accounted revenues million eur sales increased currencyadjusted compared million eur laicnanif detadilosnoc stnemetats boehringer ingelheim annual report past year companys emerging markets registered sales growth currencyadjusted sales rose million eur previous year million eur peoples republic china key driving force region currencyadjusted growth rate japan sales increased million eur currencyadjusted last years sales amounted million eur net sales region million eur currency change adjusted usa eucan emerging markets japan animal health sales animal health business amounted million eur equivalent growth currencyadjusted compared previous year net sales million eur currency change adjusted nexgard frontline heartgard ingelvac circoflex flexcombo antiparasitics swine pet antiparasitics segments developed successfully outperformed expectations drive growth increased sales pet segment usa compensated declining sales ruminant equine segments usa region especially livestock medication sales declined due tempo rary closures slaughterhouses restaurants due covid china decrease inci dence african swine fever positive impact swine segment swine vaccine ingelvac circoflex thus achieved global growth rate million eur currency adjusted however pet segment accounts three bestselling medicines boehringer ingelheims animal health business nexgard enjoyed revenues million eur million eur currencyadjusted growth level yearoveryear antiparasitic frontline achieved sales million eur improvement previous years level currencyadjusted basis heartgard another antiparasitic registered decline sales million eur million eur group management report decline sales poultry segment equine segment also unable match previous year 's strong performance primarily reflection cancellation equestrian events present innovative equine health solutions due covid decline sales alamea asia latin america middle east africa region mainly attribut able developments middle east africa region covid crisis aggravated existing economic difficulties region triggered significant decline demand especially poultry segment addition boehringer ingelheim discontinued unprofitable ruminant business india region tcm chinese market registered currencyadjusted growth financial year animal health business confronted various production supply bottlenecks covid pandemic included delays delivery raw materials active ingredients capacity constraints freight transport especially air sea freight thanks significant commitment employees particularly production sales boehringer ingelheim able ensure market supply extent possible thus minimize potential revenue losses net sales region million eur currency change adjusted usa eucan alamea tcm biopharmaceutical contract manufacturing biopharmaceutical contract manufacturing business revenue higher currency continued strong growth adjusted previous year due strong demand customers market products biopharmaceutical order situation entire business developed positively resulting high level contract manufacturing capacity utilization sales discontinued operations sales mainly contain discontinued operations winding expected discontinued operations aggregate activities minor strategic importance boehringer ingelheim include obligations income resulting business swap sanofi discontinued operations still include buscopan business brazil whose divestiture completed laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial position boehringer ingelheims financial management strategy aims safeguard companys financing means operating cash flow far possible minimize financial risks optimize cost capital million eur financial funds cash flow operating activities cash flow investing activities cash flow financing activities change financial funds cash relevant transactions change financial funds due change consolidated companies exchange rate movements valuation adjustments financial funds cash inflow operating activities amounted million eur represents increase million eur comparison previous year million eur attributable positive business performance cash outflow investing activities amounts million eur remains significantly lower previous year despite continuing high level investment strategic infrastructure business activities external innovation especially due divestiture holding hikma pharmaceuticals plc high capital milestones reached financial year terms major investments fixed expenditure volume assets expansion production facilities vienna austria biopharmaceutical contract manufacturing included first successful test runs production scale fermen tation unit invested million eur longestablished vienna site development center biopharmaceutical medicines bdc currently construction biberach also achieved important project milestones around million eur invested bdc supplementing number significant investments boehringer ingelheims global research development network jonage france boehringer ingelheim investing new antigen production center area animal health regulatory animal disease control response growing demand medicines treat footandmouth bluetongue disease due magnitude covid pandemic france investment project failed match envisaged level progress infection rates france countermeasures employed determine whether delays arise also noteworthy groups acquisition belgian company global stem cell technology nv area animal health rd cash inflow financing activities amounts million eur mainly comprises tax refunds shareholders personal taxes associated groups activities previous years well research bonuses received particular regard investments research austria group management report overall taking consideration changes within group consolidated companies well changes due exchange rate movements valuationrelated changes groups financial funds increased million eur million eur december net assets position million eur change change assets intangible tangible assets financial assets fixed assets inventories trade accounts receivable receivables current assets securities cash cash equivalents current assets assets total assets equity liabilities group equity provisions pensions similar obligations tax provisions provisions accounts payable loans thereof residual term year liabilities liabilities difference capital consolidation total equity liabilities december boehringer ingelheims total assets amounted million eur increase million eur compared previous year increase due particular rise level cash cash equivalents attributable positive cash flow financial year laicnanif detadilosnoc stnemetats boehringer ingelheim annual report despite high level investment strategic expansion companys business human pharma research germany biopharmaceuticals vienna austria fremont california usa well animal health france overall intangible tangible fixed assets decreased due depreciation amortization well exchange rate effects spite negative currency effects working capital receivables inventories increased particularly due buildup safety stocks human pharma business especially germany usa austria trade accounts receivable increased business grounds usa china particular receivables assets declined due exchange rate effects lower tax prepayments france decreases germany assets increased due higher deferred tax assets resulting temporary differences valuations consolidated companies tax balance sheets valuations consoli dated balance sheet well positive market trend plan assets pensions similar obli gations usa despite negative exchange rate effects group equity increased due group profit equity amounted million eur december equity ratio thus improved around december spite higher balance sheet total addition equity pen sion provisions longterm liabilities also available group capital long term three items totaled million eur december representing share total assets consequently previous years longterm disposable capital continues cover intangible tangible fixed assets well working capital pension provisions increased germany especially due lower actuarial discount rate increase provisions correlates change level revenue since includes provisions discounts usa royalty payments provisions environmental legal risks unclaimed vacation personnelrelated expenses also rose exchange rate effects particular opposite effect increase liabilities mainly relates liabilities well trade accounts payable germany especially liabilities declined mainly due release difference arising capital consolidation lower deferred income net assets position likewise reflects boehringer ingelheims positive development financial year boehringer ingelheim remains soundly financed company incurring considerable capital expenditure development business research activities order ensure longterm growth thus independence group management report report opportunities risks opportunities risk management assessing risks context holistic opportunities risk management also endeavor take account resulting opportunities opportunity management based strategies objectives company individual businesses operating business units integral part groupwide planning man agement systems responsible businesses functions bear direct responsibility early systematic identification analysis use opportunities boehringer ingelheim researchdriven biopharmaceutical company current research development activities naturally considered opportunity relevant projects already outlined research development rd chapter also consider digitalization opportunity see new technological possibilities areas research particularly clinical development well support patients therapy current covid pandemic giving greater priority opportunity digitalization many different areas especially sales administration aim risk management system implemented boehringer ingelheim identify busi nessspecific risks early possible particularly risks jeopardize continued existence company assess reduce reasonable level means suitable measures persons responsible key businesses functions also included process cal culating assessing risks groupwide risk information system ensures identified risks analyzed assessed carefully following appropriate classification adequate risk manage ment measures initiated implementation consistently monitored year review internal auditing performed targeted routine audits well extraordinary audits around world addition adherence legal requirements internal group guidelines main focal points functionality systems effectiveness internal controls prevention loss assets efficiency structures processes corresponding adjustments optimizations initiated necessary individual risks important risks boehringer ingelheim exposed broken follow ing specific categories financial risks legal risks production environmental risks personnel risks industryspecific risks risks identified concrete appear controllable means specific management procedures term abstract used case risks completely controlled even means targeted management procedures regardless probability occurrence financial risks relevant financial risks broken follows currency risks credit country specific risks well financial investment shareholding risks laicnanif detadilosnoc stnemetats boehringer ingelheim annual report currency risks global orientation business activities subject opportunities risks due exchange rate volatility particularly regard us dollar japanese yen also regard emerging markets currencies especially chinese renminbi group monitors quantifies risks regular intervals making predictable future business means relevant hedg ing strategies appropriate financial instruments forward exchange contracts resultant risks subsequently designated concrete controllable therefore limited credit countryspecific risks boehringer ingelheim exposed various credit countryspecific risks result interna tional business activities portfolio trade accounts receivable trade accounts payable identified extraordinary risks group beyond usual level industry since start covid pandemic also compared previous years applies possible default risks receivables largely hedged economic political risks con tinue carefully track credit countryspecific risks position respond negative changes timely manner risks consider moderate therefore regarded concrete financial investment shareholding risks group pursues defensive investment strategy management financial assets reflected orientation portfolio focused european economic mone tary union emu government bonds top credit ratings shortterm money market deposits results concrete controllable thus limited risk therefore limited opportunities major part financial investments net book value strategic investments related companies affected market business circumstances leads higher level volatility fair market value specific risks covered respective impairments consolidated financial statements legal risks business activities group exposed legal risks distinction made regula tory liability patent protection risks regulatory risks boehringer ingelheim exposed risks arising legal disputes proceedings well official investigations legal administrative decisions ongoing future proceedings predicted regard resultant risks abstract high liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim currently product liability insurance companys risk profile absolutely guarantee however insurance coverage maintained reasonable cost acceptable conditions sufficient protect boehringer ingelheim claim loss potential claims losses case foreseeable product liability insurance cover partially covers specific liability risk remaining risk exposure covered provision therefore see moderate risk group group management report furthermore product liability claims could tie substantial financial resources management capacity detrimental companys image event market considers product unsafe ineffective result unexpected side effects see abstract moderate risk patent protection risks protection innovations trademark patent rights particular importance boehringer ingelheim researchdriven biopharmaceutical company commercial protective rights increasingly target attacks breaches taken necessary precautions allow us detect threats early stage commencing appropriate countermeasures defend legal position using legal means available us factors regarded concrete moderate risks production environmental risks quality management system compliance processes continuously optimized close coop eration relevant authorities order ensure compliance cgmp standards current good manufacturing practices risks area continue high significance group classified abstract boehringer ingelheim implemented riskmitigating measures past year order counter covidspecific threats production activities include physical segre gation production teams possible obligation wear mask increase supply disinfectants inhouse initiatives testing covid status employees order protect facilitybased functions employees whose presence sitedependent asked work home order guarantee supply products market implemented measures guarantee reliable highquality supplies internal external customers addition supplier management procurement side also involves building internal standby capacities overall represents concrete moderate risk risks areas environment health safety sustainability ehss preemptively mini mized ensuring global adherence high safety standards appropriate emergency plans drawn possible incidents kind practiced subjected comprehensive quality testing regular intervals result measures risks classed concrete limited personnel risks boehringer ingelheim companies exposed demographic change resultant risk affected lack appropriately qualified personnel potential risk substantial impact companys business activities therefore included longterm planning process many years gained strategic significance result boehringer ingelheim counters risk means comprehensive personnel concept con text global personnel management also presents group opportunities regardless ethnic background gender religion offer companys employees development opportunities based professional abilities social skills personal aptitudes willingness take responsibility accordance needs company view measures described risk regarded concrete moderate laicnanif detadilosnoc stnemetats boehringer ingelheim annual report boehringer ingelheim likewise exposed human resources risks result covid pandemic pathogen spread would significant impact outside production activities company therefore closely monitoring situation vicinity sites also emphasizes working home using digital applications rather inperson meet ings curbing employee travel large extent view measures considered concrete moderate risk industryspecific risks boehringer ingelheim subject industryspecific business risks pharmaceutical industry risks partly materialized past financial year becoming increasingly important boehringer ingelheim due effects continue classed abstract high addi tion loss exclusivity products established market risks associated development registration new products risks increasingly include changing restric tive requirements relating pricing reimbursement many markets frequently prices pharmaceutical products subject state monitoring regulation also price pres sure cheaper generic drugs caused state reimbursement systems boehringer ingelheim keeping close eye various changes sales markets takes appropriate measures response current developments overall statement risk situation current perspective aware risks alone conjunction risks could lead lasting impairment companys assets financial earnings position could jeopardize continued existence boehringer ingelheim group management report report expected developments boehringer ingelheim look back successful financial year achieved ambitious targets terms absolute figures contribution wellbeing patients pets livestock able safeguard companys sustainable development profitable growth even volatile months world economy pharmaceutical industry ongoing covid pandemic difficult industry environment continue pose challenges boehringer ingelheim makes planning coming cycle dif ficult usual nonetheless look forward year ahead confidence envis age partial recovery world economy deep recession past year due expe rience last year optimistic able cope temporary setbacks new lockdowns without experiencing substantial supply problems view global efforts reduce prices medicines financial flexibility remains critical growth innovation boehringer ingelheim assuming approved vaccines med icines currently undergoing approval process help curb covid pandemic expect strong general market growth prescription pharmaceuticals focus accelerate initiative animal health business represents strategic reorientation future allow us provide customers even innovative solutions including external partnerships continu ing spread african swine fever remains significant factor despite improved situation key markets china priorities biopharmaceuticals business supplying market products contract manufacturing customers beyond launch lscc largescale production facility vienna austria remains focus expect boehringer ingelheim achieve slight yearonyear increase net sales comparable basis adjusted currency extraordinary effects consistently high rd expenditure increased compatible strategic focus continuing drive growth flow new products achieved goal obtaining rd external innovation partnerships continue actively pursue strategy invest external rd close investigation therapeutic benefit associated prospects success flow innovative medicines research pipeline shows short medium longterm growth potential anticipate significant increase rd investments new medicines also expect continue high level commitment research medicines help alleviate effects covid disease addition patent expiry attacks patents major challenges facing researchdriven pharmaceutical industry increasing amount investment rd well bigger hurdles increased costs associated product approvals also particular note previously mentioned growing cost pressure health care systems policymakers readiness contribute substantial investments needed development new medicines apparent area covid research providing vaccines therapeutics possible successfully tackle covid pandemic long term past year researchdriven pharmaceutical com panies displayed unprecedented level networking energy develop solutions extremely quickly thus proving societal value research innovation additional concrete steps laicnanif detadilosnoc stnemetats boehringer ingelheim annual report needed contribution pharmaceutical companies increased efficiency overall health care system remunerated appropriately animal health research likewise requires major investments preventive research diagnostic options conjunction long planning development cycles new products growing public cost pressure means business less predictable requires us quickly recognize seize opportu nities human pharma animal health one hand continuously monitoring adjusting costs strategies implemented measures business areas accelerate speed response changes reduce complexity organization optimize cost base way creating potential capital expenditure securing companys longterm success view increased research activities coming financial year boehringer ingelheim expects slightly lower operating result comparable basis adjusted currency extraordinary effects familyowned company boehringer ingelheims primary aim remains creation value innovation safeguards competitiveness longterm entrepreneurial independence confident achieve ambitious targets business areas thanks considerable innovative strength rests comprehensive portfolio prospec tive products global presence support highly qualified motivated employees remain committed ambition company whole research develop innovative products human veterinary medicine bring market areas high medical need break new ground therapeutic approaches aim endeavors make new medicines available humans animals treated effectively new therapies c n l e f n n c l e e n overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report laicnanif detadilosnoc stnemetats boehringer ingelheim annual report overview selected consolidated companies ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aires italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia r japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium p r mexico usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein global stem cell technology nv newport laboratories inc boehringer ingelheim evergem netherlands p r wilmington delaware biopharmaceuticals gmbh ingelheim rhein boehringer ingelheim animal health brazil p r netherlands bv velserbroek boehringer ingelheim middle east africa gmbh ingelheim rhein boehringer ingelheim animal health brasil ltda paulo new zealand p r boehringer ingelheim animal health canada new zealand limited auckland boehringer ingelheim animal health canada inc burlington philippines boehringer ingelheim animal health china p r philippines inc makati city nanchang boehringer ingelheim animal health co ltd nanchang puerto rico p boehringer ingelheim animal health boehringer ingelheim animal health shanghai co ltd shanghai puerto rico llc barceloneta boehringer ingelheim animal health operations china co ltd taizhou south africa boehringer ingelheim vetmedica china co ltd taizhou boehringer ingelheim animal health south africa pty ltd randburg denmark p south korea boehringer ingelheim animal health denmark copenhagen boehringer ingelheim animal health korea ltd seoul france p r spain boehringer ingelheim animal health france lyon boehringer ingelheim animal health espaa sa barcelona great britain p boehringer ingelheim animal health uk limited bracknell distribution p production r research development consolidated financial statements overview selected consolidated companies ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina czech republic japan p r serbia boehringer ingelheim sa boehringer ingelheim spol sro nippon boehringer ingelheim co ltd boehringer ingelheim serbia doo buenos aires prague tokyo beograd belgrade boehringer ingelheim seiyaku australia denmark yamagata south africa boehringer ingelheim pty ltd boehringer ingelheim danmark ingelheim pharmaceuticals north ryde copenhagen mexico p proprietary ltd randburg boehringer ingelheim mexico sa de austria p r ecuador cv mexico city south korea boehringer ingelheim vetmedica sa boehringer ingelheim rcv gmbh boehringer ingelheim del ecuador boehringer ingelheim korea ltd de cv guadalajara co kg vienna cia ltda quito seoul boehringer ingelheim promeco sa forschungsinstitut fr molekulare de cv mexico city pathologie gesellschaft mbh vienna finland spain p viratherapeutics gmbh rum boehringer ingelheim finland ky netherlands boehringer ingelheim espaa sa espoo barcelona belgium boehringer ingelheim bv alkmaar scs boehringer ingelheim commv france sweden brussels new zealand boehringer ingelheim france sas boehringer ingelheim aktiebolag paris boehringer ingelheim nz ltd stockholm brazil p auckland boehringer ingelheim brasl great britain switzerland r qumica e farmaceutica ltda norway boehringer ingelheim ltd boehringer ingelheim schweiz paulo bracknell boehringer ingelheim norway ks gmbh basel asker amal therapeutics sa geneva canada greece p boehringer ingelheim canada ltd boehringer ingelheim ellas ae peru taiwan toronto athens boehringer ingelheim peru sac boehringer ingelheim taiwan ltd lima taipei chile hong kong boehringer ingelheim ltda boehringer ingelheim hong kong philippines thailand santiago de chile ltd hong kong boehringer ingelheim philippines boehringer ingelheim thai ltd inc manila bangkok china p india boehringer ingelheim shanghai boehringer ingelheim india private poland turkey pharmaceuticals co ltd shanghai ltd mumbai boehringer ingelheim sp z oo boehringer ingelheim ila ticaret boehringer ingelheim warsaw istanbul biopharmaceuticals china co ltd indonesia p bh oa ehng rih na gi er ingelheim china pt boehringer ingelheim indonesia portugal usa p r investment co ltdshanghai jakarta unilfarmauniao internacional de boehringer ingelheim laboratrios farmacuticos lda boehringer ingelheim international pharmaceuticals inc lisbon trading shanghai co ltd israel wilmington delaware shanghai boehringer ingelheim fremont inc boehringer ingelheim israel ltd russia wilmington delaware tel aviv colombia ooo boehringer ingelheim moscow boehringer ingelheim usa corporation wilmington delaware boehringer ingelheim sa italy p santa f de bogot saudi arabia boehringer ingelheim italia spa vietnam milan boehringer ingelheim saudi arabia trading riyadh boehringer ingelheim animal health bidachem spa fornovo giovanni vietnam limited liability company ho chi minh city oiloftrop tcudorp boehringer ingelheim annual report consolidated balance sheet assets million eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets prepaid expenses deferred tax assets exceeding amount plan assets total assets equity liabilities million eur notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred income deferred tax liabillities total equity liabilities explanations see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement consolidated profit loss statement million eur notes net sales changes finished goods work process work capitalized operating income total revenues cost materials personnel expenses amortization intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net income noncontrolling interests group profit explanations see relevant section notes consolidated financial statements due legal requirements shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report cash flow statement million eur income taxes including noncontrolling interests amortizationreversal writedowns intangible assets depreciationreversal writedowns tangible assets change provisions pensions similar obligations including change plan assets change provisions noncash income expenses gainloss disposals fixed assets grants received change inventories change accounts receivable assets related investing financing activities change accounts payable liabilities related investing financing activities interest incomeinterest expenses income investments incomeexpenses sale businesses income taxes income taxes paid cash flow operating activities payments aquire intangible fixed assets payments aquire tangible fixed assets payments aquire financial fixed assets payments aquire generate plan assets payments relating purchase price adjustments consolidated entities investments consolidated companies proceeds disposals intangible fixed assets proceeds disposals tangible fixed assets proceeds disposals financial fixed assets cash receipts sale businesses interest received income dividends income taxes paid sale businesses cash flow investing activities consolidated financial statements cash flow statement statement changes group equity cash flow statement million eur cash receipts grants interest paid cash receipts shareholders parent company proceeds loans cash repayments loans cash flow financing activities change financial funds cash relevant transactions changes financial funds due change consolidated companies changes financial funds due exchange rate movements valuation adjustments financial funds financial funds line mainly contains aperiodic tax refunds personal taxes arising group business activities shareholders cash cash equivalents securities within current assets source funds use funds statement changes group equity balance sheet equity currency attributable non shareholders group conversion parent controlling group million eur capital reserves difference company interests equity balance withdrawals net income currency effects balance withdrawals net income currency effects balance shareholders capital consists equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements subtotals added consolidated profit loss statement furthermore individual items consolidated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company boehringer ingelheim group consists total affiliated companies germany abroad subsid iaries included consolidated financial statements ch boehringer sohn ag co kg full consolidation rules ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bears majority risks opportunities economic terms ch boehringer sohn ag co kg holds majority voting rights subsidiaries either directly indirectly accordance section hgb subsidiaries included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total amount sales equity net income year subsidiaries included consolidation accounts less aggregated group financial statements totals two subsidiaries ongoing restrictions control due terms articles association accordance section hgb companies consolidated either consolidated financial statements notes total number subsidiaries increased one compared previous year four companies acquired one company lost separate legal identity merger two affiliated companies liquidated following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim finanzierungs gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim rd beteiligungs gmbh ingelheim rhein boehringer ingelheim venture fund gmbh ingelheim rhein boehringer ingelheim invest gmbh ingelheim rhein boehringer ingelheim animal health france participations gmbh ingelheim rhein following subsidiaries exempted reporting disclosure obligations section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg hanover boehringer ingelheim participates one joint venture company included consolidated financial statements using either proportionate method equity method since material boehringer ingelheim holds interest associated companies also accounted using equity method due lack significance resulting effect groups total assets net income less oiloftrop tcudorp boehringer ingelheim annual report consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiaries consolidation first time accord ance section hgb companies included consolidation first time date company became subsidiary book value shares held parent company offset corresponding equity subsi diary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remain ing positive balance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realization principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euros using modified closing rate method accordance section hgb using modified closing rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss state ment translated euros using annual average rate resulting translation differences reported within consolidated equity reserves balance sheet currency conversion difference exchange rates groups important currencies changed follows reporting year basis eur spot rate average rate us dollar japanese yen chinese renminbi consolidated financial statements notes accounting policies fixed assets acquired tangible intangible assets carried cost less scheduled straightline amortization depreciation determined consideration technical economic circumstances based following useful lives goodwill years intangible assets years buildings years technical facilities machines years facilities operating equipment years straightline depreciation amortization used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired manufacturing costs include materials labor manufacturing costs appropriate portion materi als labor overheads depreciation fixed assets extent caused production manufacturing costs include financing costs capitalized intangible assets finite useful lives current financial year acquisition global stem cell technology nv additional milestone payment icdtherapeutics gmbh resulted total increase goodwill million eur financial assets primarily include investment securities shareholder rights loans carried lower cost fair market value impaired event reasons impairment losses recognized previous financial years longer applicable corresponding reversals recorded current assets prepaid expenses deferred income exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalized lower average acquisition prices fair market value balance sheet date finished goods work progress measured manufacturing cost basis individual calculations taking account directly attributable costs materials direct labor costs special direct costs appropriate share material production overhead costs productionrelated depreciation goods resale valued lower either acquisition cost fair market value identifiable risks inventories arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments oiloftrop tcudorp boehringer ingelheim annual report inventories valued lossfree deductions made expected sales prices reflect costs yet incurred receivables assets recognized cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets solely include securities recognized lower cost fair market valuethe stock market price reporting date cash cash equivalents consisting cash balances banks checks recognized lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred income recorded accordance section hgb includes proceeds represent income respect defined period time balance sheet date fair market value pension plan assets corresponding present value pension obligations offset according german gaap exceeding amount plan assets capitalized separately group reserves group reserves include retained earnings consolidated subsidiaries prior current years consolidation entries affect earnings difference capital consolidation difference capital consolidation reported december primarily result business swap boehringer ingelheims consumer healthcare business sanofis animal health business completed january resulted difference capital consolidation million eur difference amortized estimated period years remaining balance difference amounted million eur december difference capital consolidation primarily influenced current year release million eur income release difference arising capital consolidation included operating income release made corresponding amortization assets acquired company identified purchase price allocation previously recognized companys balance sheet consolidated financial statements notes provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judg ment including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions inter est rate results average market interest rate last ten years case provisions average market interest rate last seven years accordance rckstellungsabzinsungs verordnung german regulation discounting provisions accounts payable loans accounts payable loans recognized settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred income commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using companyspecific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting oiloftrop tcudorp boehringer ingelheim annual report notes consolidated balance sheet intangible assets acquired concessions advance million eur similar rights goodwill payments total acquisitionmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortization balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes tangible assets advance technical facilities payments land facilities operating construction million eur buildings machines equipment progress total acquisitionmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value oiloftrop tcudorp boehringer ingelheim annual report financial assets investments loans investments loans affiliated affiliated related related investment million eur companies companies companies companies securities loans total acquisitionmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders consolidated financial statements notes inventories million eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual residual million eur term year term year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders million eur previous year million eur receivables affiliated companies almost exclusively consist receivables loans receivables related companies primarily consist trade accounts receivable provisions million eur pension provisions similar obligations tax provisions provisions oiloftrop tcudorp boehringer ingelheim annual report provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data germany example g mortality tables published prof dr klaus heubeck adjusted groupspecific death probabilities invalidity rates pension obligations significant countries calculated basis following actuarial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa japan determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts million eur previous year million eur plan assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date million eur related amount pension obligations similar obligations million eur tax provisions tax provisions also include provisions double taxation risks resulted following implementation action plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps consolidated financial statements notes provisions provisions mainly include provisions discounts guarantees personnelrelated provisions provisions outstanding invoices well provisions litigation legal claims compensation damages accounts payable loans residual term residual term less thereof less million eur year year years year bank loans accounts payable thereof trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities thereof taxes million eur social security liabilities million eur previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders million eur previous year million eur presented within liabilities item accounts payable affiliated companies include loans amounting million eur previous year million eur trade accounts payable amounting million eur previous year million eur oiloftrop tcudorp boehringer ingelheim annual report notes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses provide better view earnings position cost materials partially reclassified operating expenses previous years figure adjusted million eur better comparability net sales businesses million eur human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations region million eur americas europe asiaaustraliaafrica aaa operating income operating income includes income currency translation million eur previous year million eur cost materials million eur costs raw material supplies goods resale expenditure services consolidated financial statements notes personnel expenses million eur wages salaries social benefits retirement benefits thereof retirement benefits interest effects measurement provisions pensions similar obligations shown financial income average headcount production marketing sales research development administration apprentices amortization intangible assets depreciation tangible assets amortization intangible assets depreciation tangible assets include impairment losses million eur previous year million eur operating expenses operating expenses include expenses currency translation million eur previous year million eur addition items included operating expenses mainly charges made record provisions legal risks restructuring well thirdparty services research development medicine marketing pur poses administrative expenses fees contributions commissions rent freight expenses repairs carried third parties oiloftrop tcudorp boehringer ingelheim annual report financial income million eur interest expenses similar expenses amortization loss disposal financial fixed assets shortterm investments income investment securities longterm loans interest income similar income interest expenses similar expenses item includes interest result provisions pensions similar obligations provisions amount million eur previous year million eur well interest expenses similar expenses amount million eur previous year million eur gains losses plan assets interest expense relating pension similar obligations offset accordance section sentence hgb total million eur earnings plan assets million eur interest expense relating pension similar obligations included interest result provisions pensions similar obligations provisions holding income million eur writedowns financial assets writeups financial assets income related companies thereof disposal related companies income taxes million eur current income taxes deferred taxes current income taxes primarily include corporation trade tax expenses consolidated companies total balance deferred tax assets balance sheet date amounted million eur previous year million eur deferred tax assets primarily arise difference carrying amounts provisions pension obligations discounts tax goodwill intangible assets inventories tangible assets deferred tax liabilities million eur previous year million eur recorded primarily relate differences carrying amounts intangible assets tangible assets inventories provisions consolidated financial statements notes net income net income positively influenced nonperiod income primarily reversal pro visions million eur previous year million eur negatively influenced nonperiod expenses particular taxes previous years additional expenses related provisions million eur previous year million eur notes cash flow statement cash flow statement shows changes financial funds boehringer ingelheim group resulting cash inflows outflows reporting year due development boehringer ingelheims investment strategy investments status cash equivalents according german accounting standard drs comprise increased proportion groups longterm investment securities therefore revised definition financial funds financial year financial funds merely comprise cash shortterm investments converted cash short term financial funds figure january restated ensure comparability changes balance sheet items affiliated companies included translated using average rates year balance sheet financial funds carried spot rate effect exchange rate changes financial funds shown separately financial funds december comprised following items million eur cash cash equivalents securities financial funds included million eur restricted funds balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosures contingent liabilities million eur liabilities guarantees warranties granting securities thirdparty liabilities risk utilization contingent liabilities assessed low account good net assets financial earnings position financial commitments offbalance sheet transactions million eur rental lease obligations residual financial commitments within rental lease obligations million eur previous year million eur relate longterm rental agreements subsidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilize properties fully indications time residual financial commitments include investments future effects cash flows million eur previous year million eur derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging delivery goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organizational processes set internal guidelines strict separation trading processing documentation control consolidated financial statements notes risk positions regularly tracked analyzed measured special groupwide financial report positions entered periodically reevaluated monitored fair value derivative financial instruments cal culated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions million eur recognized currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognized balance sheet date derivative financial instruments included hedge accounting valuation units follows nominal value fair value million eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecast transactions accordance section hgb met foreign currency forward exchange contracts recognized balance sheet line net hedge presentation method following accounting policies apply recognition valuation units accordance section hgb economic hedges accounted financial statements using valuation units valuation units recognized foreign currency based net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation units oiloftrop tcudorp boehringer ingelheim annual report december hedges highly probable forecasted net cash flows recognized follows january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy january february net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy consolidated financial statements notes january february net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd furthermore december valuation units foreign currency receivables recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value rub rub rub pln pln pln december valuation units foreign currency receivables resulting loans recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value aud aud aud brl brl brl cny cny cny czk czk czk mxn mxn mxn pln pln pln rub rub rub thb thb thb usd usd usd amount hedged foreign currency risk correlates relative change exchange rate planning date realization date forecasted transactions currencies appreciate depreciate euro would foreign currency risk million eur without hedging oiloftrop tcudorp boehringer ingelheim annual report research development expenses million eur research development expenses noncapitalized research development expenses include among items costs associated clinical studies total auditor fees total fees charged group auditor financial year amounted million eur million eur relates audits financial statements million eur assurance services million eur tax advisory services million eur services subsequent events december boehringer ingelheim undertook purchase shares swiss biotech com pany nbetherapeutics ag overall price million eur purchase price consists payment made completion transaction well future performancerelated payments depending achieve ment certain clinical regulatory milestones transaction completed january date acquisition boehringer ingelheim held interest around nbetherapeutics fully consolidated subsidiary since end financial year become aware events material signif icance group could lead reappraisal net assets financial earnings position shareholdings list companies included consolidated financial statements complete list shareholdings presented accordance section hgb included audited consolidated financial statements submitted german federal gazette ingelheim rhein march boehringer ag board managing directors hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer independent auditors report independent auditors report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statements audit opinion group management report audited consolidated financial statements ch boehringer sohn ag co kg ingelheim rhein subsidiaries group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement changes group equity financial year january december notes consolidated financial statements including recognition measurement policies presented therein addition audited group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consoli dated financial statements audit opinion group management report accompanying consol idated financial statements comply material respects requirements german commercial law give true fair view assets liabilities financial position group december financial performance financial year january december compliance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified opinion consolidated financial statements audit opinion group management report contrary section number letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recog nized former members board managing directors disclosed notes consolidated financial statements conducted audit consolidated financial statements group management report accord ance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report independent group entities accordance requirements german commercial oiloftrop tcudorp boehringer ingelheim annual report professional law fulfilled german professional responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinions consolidated financial statements group management report information management responsible information information comprises annual report exception audited consolidated financial statements group management report auditors report opinions consolidated financial statements group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report audited content knowledge obtained audit otherwise appears materially misstated responsibilities management consolidated financial statements group management report management responsible preparation consolidated financial statements comply material respects requirements german commercial law consolidated financial statements com pliance german legally required accounting principles give true fair view assets liabilities finan cial position financial performance group addition management responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements management responsible assessing groups ability continue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore management responsible preparation group management report whole pro vides appropriate view groups position material respects consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development addition management responsible arrangements measures sys tems considered necessary enable preparation group management report accord ance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report independent auditors report auditors responsibilities audit consolidated financial statements group management report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent con solidated financial statements knowledge obtained audit complies german legal require ments appropriately presents opportunities risks future development well issue auditors report includes opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial state ments group management report exercise professional judgment maintain professional skepticism throughout audit also identify assess risks material misstatement consolidated financial statements group management report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinions risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal controls obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing opinion effectiveness systems evaluate appropriateness accounting policies used management reasonableness estimates made management related disclosures conclude appropriateness managements use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements group management report disclosures inadequate modify respective opinions conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease able continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles oiloftrop tcudorp boehringer ingelheim annual report obtain sufficient appropriate audit evidence regarding financial information entities business activ ities within group express audit opinions consolidated financial statements group man agement report responsible direction supervision performance group audit remain solely responsible audit opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides perform audit procedures prospective information presented management group management report basis sufficient appropriate audit evidence evaluate particular significant assump tions used management basis prospective information evaluate proper derivation prospective information assumptions express separate opinion prospective infor mation assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version signed kneisel krau wirtschaftsprfer wirtschaftsprfer german public auditor german public auditoroiloftrop tcudorp pages p r u c p r f l e l e c n human pharmaceuticals animal health boehringer ingelheim annual report respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma among bronchial asthma chronic inflammatory disorder prevalent chronic diseases frequent cause airways inflammation accompanied airway hyper morbidity premature deaths worldwide responsiveness leads narrowing airways recurrent episodes wheezing breathlessness coughing idiopathic pulmonary fibrosis ipf rare disease symptoms occur particularly night early severely debilitating ultimately lethal hours morning known asthma trig gered genetic environmental factors eg allergens copd viral infections unlike copd asthma occur early copd chronic disease lungs causes coughing childhood also present adolescents adults excessive mucus production dyspnea ultimately asthma often underestimated easytomanage condi destroys lung tissue alveoli thus gas exchange tion however almost one two patients asthma still affected leads limitation airflow causing experience symptoms receiving maintenance therapy shortness breath respiratory symptoms air putting increased risk potentially lifethreatening flow limitation partially reversible usually worsens asthma exacerbations addition patients often adjust time leading disability ultimately death symp daily lives accommodate conditions avoid physical toms excess cough breathlessness main exertion daytoday activities negative impact reasons copd stressful patients lung emphy quality life sema chronic bronchitis main manifestations copd copd caused continuous damage lungs resulting inhaling pollutants primarily cigarette smoke however factors also need considered including indoor outdoor air pollution course copd disease occurs second half humans life character ized accelerated loss lung function compared mal ageing occasional sudden worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms thus inactivity product portfolio human pharmaceuticals indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients copd pulmonary disease copd spiriva handihaler including chronic bronchitis emphysema spiriva respimat maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance bronchodilator treat ment patients aged six years older severe asthma experienced one severe asthma exacerbations past year spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow obstruction pulmonary disease copd stiolto respimat olodaterol hydrochloride patients chronic obstructive pulmonary inspiolto respimat disease copd chronic obstructive striverdi respimat olodaterol hydrochloride maintenance treatment patients chronic pulmonary disease copd obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination shortacting anticholinergic associated obstructive salbutamol sulphate betaadrenergic management airway diseases reversible bronchospasms associated obstructive airway diseases patients requir ing one bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic obstructive chronic bronchitis pulmonary disease copd mild moder bronchial asthma ate bronchial asthma adulthood child hood supplement betaagonists cases acute asthma chronic obstructive airway berodual ipratropium bromide prevention treatment symptoms disorders bronchodual fenoterol hydrobromide chronic obstructive airway disorders duovent reversible airflow limitation bronchial asthma especially chronic bronchitis without emphysema boehringer ingelheim annual report respiratory diseases continued idiopathic pulmonary fibrosis ipf chronic fibrosing interstitial lung diseases ipf chronic progressive lung disease associated ilds progressive phenotype beyond markedly reduced life span affecting many peo idiopathic pulmonary fibrosis ipf ple per worldwide ipf characterized progressive interstitial lung diseases heterogeneous group scarring lung tissue loss lung function time mostly rare conditions lung run risk development scarred tissue called fibrosis time developing pulmonary fibrosis fibrosis pathological mul tissue thickens stiffens scarring lungs lose tiplication connective tissue leading usually chronic ability take transfer oxygen blood irreversible scarring lung tissue course inter stream vital organs get enough oxygen result stitial lung disease may develop progressive fibrosing individuals ipf experience shortness breath even ild leading decline function associated increased resting often difficulty coping demands morbidity mortality idiopathic pulmonary fibrosis ipf everyday life due limited physical capacity phenotype chronic fibrosing ild course dis ease symptoms similar chronic pfilds despite acute ipf exacerbations defined rapid deteriorations underlying ild diagnosis average ild patients symptoms lung function within days weeks develop progressive pulmonary fibrosis events occur point course disease even first presentation associated high mortality patients ipf risk acute ipf exacerbations systemic sclerosis associated interstitial lung disease sscild systemic sclerosis ssc also known scleroderma rare incurable autoimmune disease affecting connective tissue disease estimated affect people every europe million worldwide ssc impacts four times many women men onset disease typically occurs young age years cause scarring fibrosis skin well major organs heart lungs digestive tract kidneys lifethreatening complications approximately patients develop significant pulmonary involvement within three years diagnosis ssc affects lungs cause intersti tial lung disease ild known sscild key driver mortality among people ssc accounting approxi mately one third deaths product portfolio human pharmaceuticals indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bron chiale symptomatic treatment allergic non allergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients bron allergic rhinitis flurinol chial asthma prophylaxis symptomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib countries treatment ipf patients idiopathic pulmonary fibrosis ipf systemic sclerosis associated countries therapy interstitial lung disease sscild slow rate decline sscild pulmonary function chronic fibrosing interstitial lung diseases ilds countries treatment progressive phenotype chronic fibrosing interstitial lung diseases ilds progressive phenotype beyond ipf boehringer ingelheim annual report cardiovascular metabolic diseases cardiovascular cv disease leading cause death prevention treatment venous worldwide still increasing prevalence currently thromboembolism responsible nearly one three deaths worldwide one key venous thromboembolism vte umbrella term risk factor developing cardiovascular disease pres encompasses deep vein thrombosis dvt pulmonary ence diabetes people type diabetes two four embolism pe dvt occurs thrombus blood clot forms times likely develop cardiovascular disease peo deep vein commonly leg partially com ple without diabetes result life expectancy pletely blocks flow blood thrombus grows por years shorter proper control diabetes treat tion may break away main clot travel circu able risk factors therefore vital prevention cardio latory system lungs lodging blood clot vascular events arteries lung called pe vte serious disorder potentially fatal consequences stroke stroke rapidly developing loss brain functions caused patients undergoing orthopedic surgery considerable disrupted blood flow affected brain tissue risk developing dvt chronic venous insufficiency due ischemia lack blood supply caused thrombo pulmonary hypertension may develop longer term sis embolism due bleeding hemorrhagic stroke prevent vte events consequences orthopedic result affected area brain unable function surgery patients receive kind thromboprophy damage quickly becomes permanent untreated stroke laxis patients already suffered vte require anti acute event requiring emergency diagnosis interven coagulant treatment secondary prevention recurrent tion worldwide stroke one leading causes death thromboembolic event longterm disability reversing anticoagulation symptoms transient ischemic attack tia similar anticoagulation therapy offers important benefits patients stroke last minutes hours risk thromboembolic events however even though rare result permanent neurological damage tia may pre may situations rapid reversal anticoagulation cede stroke emergency medical care subsequent pre medically necessary eg patient taking anticoagulant ventive treatment may necessary involved severe car accident needs emergency surgery atrial fibrillation atrial fibrillation af common sustained heart rhythm condition affecting approximately total pop ulation one four adults develops af lifetime patients af higher risk developing blood clots upper left heart chamber cause stroke clot breaks loose travels brain af leads fivefold increase risk stroke resulting three million patients worldwide suffering afrelated strokes year patients af risk stroke reduced appropri ate anticoagulation therapy product portfolio human pharmaceuticals indications brand names active ingredients stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients atrial fibrillation primary prevention venous prazaxa primary prevention venous thromboembolic thromboembolic events events vte adults elective total hip orthopedic surgery knee replacement surgery treatment secondary prevention venous treatment deep vein thrombosis dvt thromboembolic events pulmonary embolism pe secondary prevention recurrent dvt pe adults specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated adult patients treated pradaxa dabigatran etexilate rapid reversal anticoagulant effects required emergency surgeryurgent procedures lifethreatening uncontrolled bleeding hypertension micardis telmisartan treatment hypertension reduction cardiovascular morbidity risk myocardial infarction heart attack mortality prevention stroke death cardiovascular cv causes patients years age older high risk developing major cv events unable take ace inhibitors us reduction cardiovascular morbidity patients manifest atherothrombotic car diovascular disease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus documented target organ damage eu hypertension micardisplus telmisartan treatment hypertension alone micardis plus hydrochlorothiazide antihypertensive agents lower blood pres micardis hct sure lowering blood pressure reduces risk comicardis fatal nonfatal cardiovascular events primarily strokes myocardial infarctions indicated initial therapy us treatment essential hypertension micardisplus fixed dose combination indicated adults whose blood pressure adequately controlled telmisartan alone eu boehringer ingelheim annual report cardiovascular metabolic diseases continued hypertension cardiovascular diseases hypertension high blood pressure chronic disease blood pressure chronically elevated hypertension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal anti hypertensive treatment prevent cardiovascular events reduce risk cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack occurs thrombus blood clot suddenly prevents blood flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attacks one common causes death industrialized countries product portfolio human pharmaceuticals indications brand names active ingredients hypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial therapy micardis amlo patients likely need multiple antihypertensive micardis duo agents achieve blood pressure goals us addon therapy adult patients ade quately controlled blood pressure amlodip ine replacement therapy adult patients receiving telmisartan amlodipine separate tablets eu acute ischemic stroke actilyse alteplase fibrinolytic treatment acute ischemic stroke acute myocardial infarction actilyse cathflo acute myocardial infarction acute massive acute massive pulmonary pulmonary embolism fibrinolytic treatment embolism occluded catheters catheter clearance due thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke following initial first stroke transient ischemic asasantin acetylsalicylic acid stroke transient ischemic attacks tia attacks tia asasantin retard acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction hypertension catapresan clonidine treatment hypertension catapres clonidine hydrochloride catapressan boehringer ingelheim annual report cardiovascular metabolic diseases continued diabetes cardiorenalmetabolic system collaborative multidisciplinary team approach optimize type diabetes chronic progressive condition associated patient care coordinating treatment related comorbidi elevated blood sugar levels people type diabetes ties including use emerging medications broad high burden comorbidities risk factors cardiovascular renal metabolic effects help improve include heart failure kidney disease hypertension obe outcomes people serious chronic conditions sity cardiorenalmetabolic conditions affect one billion people worldwide leading cause death effective treatment people type diabetes addition diet exercise demands early balanced multi disciplinary approach interconnected nature cardio renalmetabolic systems requires addressing blood sugar control cardiovascular risk factors short term reducing overall risk disease progression associated heart kidney complications long term product portfolio human pharmaceuticals indications brand names active ingredients type diabetes mellitus jardiance empagliflozin treatment adults type diabetes melli jardianz tus adjunct diet exercise improve glycemic control reduce risk cardiovascular death adults type diabetes mellitus established cardiovascu lar disease us indication december label varies country please refer local product information type diabetes mellitus synjardy empagliflozin treatment adults type diabetes melli jardiance duo metformin tus adjunct diet exercise improve jardianz duo hydrochloride glycemic control treatment synjardy xr empagliflozin metformin appropriate us indication december label varies country please refer local product information type diabetes mellitus glyxambi empagliflozin linagliptin treatment adults type diabetes melli tradiance tus adjunct diet exercise jardianz dpp improve glycemic control adults type diabetes mellitus empagliflozin linagliptin appropriate treatments us indication march label varies country please refer local product information type diabetes mellitus trajenta linagliptin treatment adults type diabetes tradjenta mellitus adjunct diet exercise trazenta improve glycemic control used monotherapy trayenta metformin tolerated contraindicated combination therapy type diabetes mellitus jentadueto linagliptin metformin treatment adults type diabetes trayenta duo hydrochloride mellitus adjunct diet exercise trajenta duo improve glycemic control treatment trajentamet metformin lead sufficient control jentadueto xr patients treated trajenta linagliptin metformin diabetes portfolio collaboration eli lilly company boehringer ingelheim annual report oncology cancer threat global health estimated different subtypes small cell lung cancer million new cases cancer diagnosed worldwide sclc nonsmall cell lung cancer nsclc ten million people died cancer nearly one six global different molecular genetic aberrations mutations present deaths world cancer factsheet com tumor identified focusing molecular mon diagnosed cancer types lung cancer nearly changes specific respective subtype lung breast cancer nearly colorectal cancer prostate cancer targeted therapies become effective cancer stomach cancer treatments show survival benefit time less harmful normal cells thereby reducing side lung cancer effects lung cancer refers malignant abnormal cell growth inside lung tissue common cancer esti mated million new cases per year worldwide smok ing primary cause disease contributing almost cases recently however incidence lung cancer among nonsmokers increased lung cancer poor prognosis million deaths per year representing nearly cancer deaths lung cancer symptoms unspecific disease may take many years appear late diagnosis advanced stage disease results often dismal prognosis lung cancer patients surviving five years following diagnosis product portfolio human pharmaceuticals indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib firstline treatment adult patients locally nsclc gilotrif advanced metastatic nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations treatment patients locally advanced metastatic nsclc squamous histology progressing platinumbased chemotherapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally recurrent nonsmall cell lung cancer nsclc adenocarcinoma tumor histology firstline chemotherapy boehringer ingelheim annual report diseases central nervous system mental neurological diseases depression associated pd depression sleep disorders parkinsons disease significantly impact patients primary symptoms result lack neuro families also substantial burden society transmitter dopamine distinct areas human brain parkinsons disease restless legs syndrome rls parkinsons disease pd degenerative disorder cen restless legs syndrome rls common neurological disor tral nervous system patients usually notice motor symptoms der characterized uncontrollable urge move legs like hand shaking tremor first sign disease primarily occurring evening night hours usually may progress include shaking arms legs accompanied unpleasant sometimes painful sensa head motor symptoms may develop time tions legs well disturbed sleep resulting daytime include stiffness often results loss facial expression tiredness sleepiness sensations felt deep within gradual slowing loss motion freezing legs described creeping crawling aching patients also suffer nonmotor symptoms infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symp toms infections resulting damage human immune system caused human immunodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals sus ceptible opportunistic infections tumors babies infected mothers risk getting virus preg nancy childbirth breastfeeding product portfolio human pharmaceuticals indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex pramipexole dihydrochloride parkinsons disease may used mono mirapexin monohydrate therapy combination levodopa pexola symptomatic treatment idiopathic moderate mirapex er severe restless legs syndrome sifrol er sleep disorders lendormin brotizolam shortterm treatment disorders initiating maintaining sleep insomnia requiring pharmacological inter vention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv infection viramune xr several countries prevention mothertochild transmission hiv preg nant women taking antiretroviral therapy time labor prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treat elodius ment hivinfected patients coadminis tered mg ritonavir treat mentexperienced infected hiv strains resistant one protease inhibitor boehringer ingelheim annual report livestock swine infectious respiratory diseases integrated health management ihm ingelvac circoflex first singledose piglet vaccine farmera soundtalks empower pig pro control porcine circovirus disease pcvd ingelvac ducers breeders retailers consumers improve health circoflex contains impranflex adjuvant allows animal welfare efficiency giving insights predictions fresh mixing ingelvac mycoflex form flexcombo recommendations ihm solutions twistpak system ingelvac prrs products licensed active immunization respiratory reproductive form porcine reproductive respiratory syn drome prrs ingelvac provenza protects multiple iavs strains providing protection pigs vulnerable infectious enteric diseases enterisol ileitis first oral live vaccine ileitis globally prevalent enteric disease swine caused lawsonia intracellularis licensed improve weight gain reduce growth variability associated disease enterisol ileitis helps reduce total anti microbial use pork production product portfolio animal health indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunization pigs diseases porcine circovirus age two weeks porcine circovirus type pcv type reduce mortality clinical signs including weight loss lesions lym phoid tissues associated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viremia infectious respiratory ingelvac prrs mlv attenuated live vaccine depending product active diseases ingelvac prrsflex eu prrs virus type type immunization pigs various ages reprocyc prrs eu porcine reproductive respiratory syndrome virus prrs infectious respiratory ingelvac mycoflex inactivated vaccine active immunization pigs diseases mycoplasma age three weeks reduce lung lesions hyopneumoniae following infections mycoplasma hyopneumoniae infectious respiratory ingelvac provenza attenuated live influenza vaccine vaccination pigs one day age diseases laiv older influenza virus strains hn hn infectious enteric disease enterisol ileitis attenuated live vaccine active immunization pigs lawsonia intracellularis age three weeks intestinal lesions caused lawsonia intracellularis infection reduce growth variability loss weight gain associated disease respiratory diseases soundtalks sound monitors gateways soundtalks sound monitoring technology algorithms detects early symptoms respiratory dis tress swine thanks monitoring algorithms data capture forms tools farmera mobile app digital data management farmera allows efficient effec communication platform swine tive proactive enabling evidencebased production decision making realtime information managing health production production companies soundtalks trademark soundtalks nv boehringer ingelheim annual report livestock cattleruminants cattleruminants business global leader antiparasitic brands ivomec longrange eprinex world renowned parasiticides treat protect grazing animals harmful effects internal external parasites zactran treats cattle bacterial pneumonia sheep digital dermatitis infections bovela active immunization cattle three months age terms reproductive infectious diseases product portfolio animal health indications brand names active ingredients internal external ivomec ivermectin depending formulation product parasites cattle treatment nematodes lice mites ticks flies lungworms liver flukes internal external longrange eprinomectin longacting theraphase technology used develop parasites cattle formulation eprinomectin allows single treatment last days long enough break parasite life cycle effectively reduce parasite burdens pasture longrange effective con trol internal external parasites cattle gastrointestinal roundworms lung worms grubs mites internal external eprinex eprinomectin depending formulation product parasites ruminants treatment nematodes lice mites ticks flies lungworms cattle sheep bacterial causes zactran gamithromycin depending species indication country respiratory disease registration product treat interdigital dermatitis ment metaphylaxis control respiratory footrot disease cattle caused key bacteria mannheimia pasteurella histophilus mycoplasma footrot disease sheep caused key bacteria fusobacterium dichelobacter reproductive infectious bovela bovine viral diarrhoea bvd reduces hyperthermia minimizes diseases cattle types reduction leukocyte count caused bovine viral diarrhoea virus bvdv bvdv reduces virus shedding viremia caused bvdv prevents birth persistently infected calves caused transplacental infec tion boehringer ingelheim annual report livestock cattleruminants continued vaccine pyramidpresponse part expanding portfolio respiratory reproductive vaccines prevent dis eases affect livestock metacam nonsteroidal antiinflammatory drug nsaid helping minimize losses inflammation tissue dam age animals suffering disease hence addressing need maintained profitability concern farm ani mal wellbeing product portfolio animal health indications brand names active ingredients infectious respiratory pyramid family multivalent vaccine combina pyramidpresponse family vaccines diseases reproductive presponse tions including different modified live provides broad coverage bvd types disorders cattle viruses bovine viral diarrhoea bvd ibr brsv pi mannheimia haemolyt types infectious bovine rhino ica single dose contain tracheitis ibr parainfluenza pi metastim adjuvant system enhance bovine respiratory syncytial virus animals response greater protection us brsv bacteria pasteurella canada multocida mannheimia haemolytica metastim registered trademark zoetis services llc l canicola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona pain inflammatory metacam meloxicam treatment mastitis lactating cows disorders control pain associated dehorning surgery also indicated use calves affected diarrhoea cattle suffering respiratory disease boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consists significant range live inactivated vaccines broilers layers breeder hens providing protection critical viral bacterial diseases like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syn drome avian coryza portfolio preventive products helps producers worldwide provide safe affordable abun dant sustainable highquality poultry meat eggs product portfolio animal health indications brand names active ingredients various viral bacterial gallimune polyvalent attenuated live inacti vaccination healthy chickens diseases poultry gallivac vated vaccine containing antigens diseases caused included antigens volvac vaccination avian influenza prevention common diseases newcastle disease avian coryza broiler chickens diseases responsible egg drop syndrome losses egg production layers infectious bronchitis infectious bursal disease gallibacterium anatis infectious bursal disease vaxxitek hvt ibd serotype live mareks disease vector vaccination dayold embryos ibd mareks disease md vaxxitek hvt ibd nd live vhvt recombinant virus onedayold chickens effective newcastle disease nd vaxxitek hvt ibd ilt contains gene ibd virus standard variant infectious bursal dis infectious laryngotracheitis trivalent vaccines gene ease mareks disease trivalent ilt ibd virus nd ilt viruses vaccines newcastle disease infec diluent tious laryngotracheitis newcastle disease nd avinew live newcastle disease virus broiler chickens one day age active vggaavinew strain immunization newcastle disease reduce mortality clinical signs associated disease future layer future breeder pullets age four weeks priming active immu nization egg drop caused newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lay mareks disease prevexxion rn live herpes virus chimera vaccination dayold embryos prevexxion rnhvt serotype strain rn andor onedayold chickens recommended prevexxion diluent protect virulent mareks rnhvtibd disease prevexxion rn vaxxitek hvtibd newcastle mareks newxxitek hvt nd live mareks disease vectored vaccination dayold embryos diseases virus serotype contains onedayold chickens effective gene insert newcastle mareks disease newcastle disease disease diluent boehringer ingelheim annual report veterinary public health vph work governments private partners toward btvpur alsap multistrain vaccine used active immu improving control eradicating diseases footand nization sheep cattle prevent viremia reduce mouth disease bluetongue virus rabies clinical signs caused bluetongue virus footandmouth fmd vaccines portfolio including aftopor aftovaxpur aftovax provides active immu nization cattle sheep pigs reduce clinical signs mortality following exposure fmd virus rabisin inactivated vaccine rabies available clear colorless suspension injection raboral vrg oral recombinant vaccine protects wildlife rabies product portfolio animal health indications brand names active ingredients footandmouth disease aftopor mix inactivated fmd virus antigens aftopor aftovaxpur highly potent fmd aftovaxpur widest range vaccine strains vaccines purified antigens recommended aftovax endemic emergency situations aftovaxpur doe potential marker properties allow differentiation infected vacci nated animals diva aftovax lowcost effective vaccine profile cattle sheep suitable mass vaccination endemic situations aftovaxpur doe suitable emergency situations rabies rabisin rabisin inactivated adjuvanted rabisin used active immunization raboral vrg rabies virus dogs cats reduce mortality clinical raboral vrg vacciniavectored rabies signs due rabies infection immunity vaccine demonstrated one month vaccina tion shown persist first booster dose year primary vacci nation years following booster vaccination raboral vrg oral rabies recombinant vaccine protects wildlife raccoons foxes coyotes rabies thereby reducing risk exposure rabies humans domestic animals sold government agencies conducting rabies control programs bluetongue btvpur alsap mix inactivated bluetongue virus active immunization sheep prevent viremia reduce clinical signs caused bluetongue virus serotypes andor combination maximum serotypes active immunization cattle prevent viremia caused bluetongue virus serotypes andor reduce clinical signs caused bluetongue virus serotypes combination maximum serotypes onset immunity demonstrated three weeks five weeks sheep btv primary vaccination course btv btv cattle btv btv serotypes boehringer ingelheim annual report companion animals horse equine portfolio highly comprehensive covering key eqvalanzimecterin contains ivermectin leading ingredi aspects equine health including parasite control vaccina ent controls wide variety important internal parasites tion management chronic diseases range including bots benzimidazoleresistant small strongyles flagship products treatment colic joint disease easytoadminister oral paste eqvalanzimecterin respiratory disease latter two categories recently approved adult horses foals young six weeks age enhanced addition new innovative products also line nutraceuticals bought without eqvalan duogold zimecterin gold combines ivermectin prescription praziquantel ingredient specifically controls tape worms prascend indicated treatment pituitary pars inter media dysfunction ppid also known equine cush articell forte worlds first licensed veterinary stem cell ings disease clinical signs ppid hypertrichiosis lamini product readytouse intraarticular injection tis change body conformation lack performance chondrogenic induced mesenchymal cells treatment treatment prascend lifelong lameness linked noninfective joint inflammation horses articell forte one latest additions equine vetera vaccines first us vaccine portfolio include portfolio available range countries within eu multiple convenient combinations disease protection approvals expected due course horses young four months age vaccines pro tect many nine infectious organisms including aservo equihaler first inhalation product influenza herpes west nile virus tetanus others treatment severe equine asthma product novel glu enables customized protection horse limited nee cocorticoid prodrug ciclesonide inhalation solution deliv dle injections ered inhaler specifically designed use horses implementing soft mist technology derived gastrogardulcergard indicated treatment respimat inhalers human pharma exciting new intro prevention equine gastric ulcers one duction gained final authorization product availability common diseases horses gastrogard supplied eu us canada approvals easytouse oral paste form first choice countries expected due course treatment gastric ulcers since launch ulcergard usa preventive choice horses increased risk developing gastric ulcers product portfolio animal health indications brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs dysfunction ppid associated pituitary pars intermedia dysfunction ppid also known equine cushings disease combination vaccine vetera eastern western venezuelan vaccination healthy horses aid nine common diseases encephalomyelitis tetanus west nile prevention diseases caused horses virus equine herpes virus equine included antigens us canada influenza viruses equine gastric ulcers gastrogard omeprazole treatment prevention gastric ulcers ulcergard prevention recurrence gastric ulcers horses foals four weeks age older internal parasites eqvalan ivermectin treatment prevention parasitic zimecterin ivermectin praziquantel infestations horses donkeys due eqvalan gold large small strongyles ascarids eqvalan duo goldduo includes treatment tape zimecterin gold worms r eduction mild moder articell forte chondrogenic induced equine treatment mild moderate lameness ate recurrent lameness asso allogeneic peripheral bloodderived linked noninfective joint inflammation ciated nonseptic joint mesenchymal stem cells horses contains stem cells inflammation horses obtained equine blood stem cells develop types cells stem cells active substance mesenchymal stem cells treated develop cartilage cells severe equine asthma aservo equihaler ciclesonide inhalation solution alleviation clinical symptoms severe equine asthma characterized coughing nasal discharge nasal flaring increased breathing effort rest abnormal lung sounds boehringer ingelheim annual report companion animals pets pet portfolio offers diverse solutions heartgard plus contains active ingredients ivermectin important needs canine feline health including indus pyrantel soft beef chew given monthly iver tryleading parasiticides vaccines therapeutics address mectin effective preventing deadly heartworm disease major chronic diseases heart failure kidney diseases hyper pyrantel effective treatment control round tension epilepsy diabetes mellitus osteoarthritis worms well hookworms heartgard launched first monthly heartworm preventative still years frontline leader flea tick con bestselling heartworm preventative world trol dogs cats one trusted brands animal health frontline continues bring innovation broadline offers cat owners allinone convenience provid category recent launch frontline triact ing confidence cat broadest possible protec features repellency insecticidal efficacy many tion protects cats broadest spectrum internal diseasecarrying flying insects decreases risk external parasites including adult fleas flea eggs flea transmission vectorborne pathogen larvae ticks heartworms hookworms roundworms vesical worms tapeworms nexgard contains active ingredient afoxolaner first oral medication treat fleas ticks dogs vetmedin inodilator become standard efficacy palatable beefflavored soft chew care treating dogs congestive heart failure caused formulation nexgard currently bestselling pet medi dilated cardiomyopathy valvular insufficiency mitral andor cation animal health industry tricuspid regurgitation significantly improves clinical signs extends life expectancy patients recent studies nexgard spectra combines flea tick efficacy afox also shown used asymptomatic cases olaner nexgard broadspectrum deworming ingre either dilated cardiomyopathy doberman pinschers val dient milbemycin oxime beefflavored chew vular insufficiency vetmedin significantly delays onset nexgard spectra effective treating flea tick clinical signs congestive heart failure first veterinary mite infestations well gastrointestinal parasites infections cardiology also protects dogs deadly parasites heart worm lungworm data file babesia canis transmitted dermacentor reticulatus ticks ehrlichia canis transmitted rhipicephalus sanguineus ticks leishmania infantum transmitted phlebotmine sandflies data file data file product portfolio animal health indications brand names active ingredients antiparasitic caninefeline frontline fipronil frontline plusfrontline combo external parasites frontline combo fipronilsmethoprene launched innovative combination frontline plus fipronilpermethrin continue frontline story indicated frontline triact treatment prevention flea tick frontect lice infestations also breaks flea life cycle preventing development flea immature stages frontline triactfrontect indicated treatment prevention flea tick infestations dogs also provides repel lent activity mosquitoes sandflies ticks reducing risk transmission vectorborne pathogens antiparasitic canine nexgard afoxolaner nexgard delivered highly palatable external parasites beefflavored chew indicated treatment prevention flea tick infestations dogs also indicated prevention borrelia burgdorferi infections usa treatment demodex sarcoptes otodectes mite infestations nonus geographies antiparasitic canine nexgard spectra afoxolaner nexgard spectra delivered highly internal external milbemycin oxime palatable beefflavored chew indicated parasites treatment andor prevention flea tick mite infestations also prevents heart worm disease angiostrongylosis thelazio sis treats hookworm roundworm whip worm infestations dogs antiparasitic canine heartgard plus ivermectin use dogs prevent canine heartworm internal parasites pyrantel disease eliminating tissue stage heartworm larvae month days infection treatment control roundworms hookworms antiparasitic feline broadline fipronil smethoprene protects cats broadest spectrum internal external eprinomectin internal external parasites including adult parasites praziquantel fleas flea eggs flea larvae ticks heartworms lungworms hookworms roundworms vesical worms tapeworms congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilated cardiomyopathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopathy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter doberman pin schers treatment dogs myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increased heart size delay onset clinical symptoms heart failure boehringer ingelheim annual report companion animals pets continued boehringer ingelheim complete trusted semintra firstever licensed angiotensin receptor proven range products services pain management blocker veterinary use specifically designed cats choosing portfolio gives veterinarians freedom semintra scientifically advanced treatment one sim tailor treatment patient provides access value ple solution safely effectively harnesses protective added veterinary services benefits cats reninangiotensinaldosterone system protect kidneys key organs semintra available metacam offers extensive range formulations indi mgml mgml oral solution semintra mgml cations making complete nonsteoridal antiinflamma first launched reduction proteinuria associ tory drug nsaid dogs cats guinea pigs enables ated chronic kidney disease cats semintra veterinarians better achieve goals pain management mgml launched control ustreatment eu gives owner pet exactly product need feline systemic hypertension first vetlicensed product ample longterm studies support products safety effi feline hypertension us cacy led multiple indications across diverse species since launch prozinc become proven liquid formulation metacam dogs makes easy insulin choice feline patients owners conve titrate lowest effective dose liquid formulation nient management feline diabetes approval cats easy administer improved dog administration prozinc canine patients opportunity syringe aimed achieve better accuracy introduced become firstchoice solution successful management diabetes dogs cats large clinical studies europe previcox designed specifically dogs us japan confirmed majority dogs selective veterinary cox inhibitor previcox provides safe managed one injection prozinc insulin per day sustained pain relief fast onset action longterm major breakthrough dogs owners veterinarians safety efficacy established large field studies previcox shown efficacious pet vaccine product portfolio includes purevax feline competition acute models osteoarthritis vaccines formulated provide effective protection without use adjuvants recombitek providing targeted protection dogs recombinant technology decades proven efficacy safety rabies rabisin imrab product portfolio animal health indications brand names active ingredients pain inflammatory metacam meloxicam metacam used reduce specific types diseases postoperative pain inflammation well musculoskeletal disorders dogs cats pain inflammatory previcox firocoxib relief pain inflammation diseases associated osteoarthritis well specific types postoperative pain dogs chronic kidney disease semintra telmisartan management chronic kidney disease ckd ckd cats feline systemic hypertension us eu cats hypertension cats diabetes prozinc protamine zinc treatment diabetes mellitus cats dogs achieve reduction hyperglycemia improvement associated clinical signs feline vaccines portfolio purevax feline herpes virus purevax fully adjuvantfree feline feline calicivirus vaccine range leverages innovative feline panleukopenia virus canarypox technology felv rabies chlamydia felis also offers sustained protection rabies recombinant vectored feline three years leukemia virus recombinant vectored rabies virus canine vaccines portfolio recombitek recombinant vectored canine recombitek features complete line distemper virus canine vaccines including canine parvovirus recombitek lyme vaccine canine adenovirus type contains ospa nonadjuvant formulation canine parainfluenza virus canine coronavirus recombitek oral bordatella effective leptospira canicola safe protection made easy leptospira grippotyphosa leptospira icterohaemorrhagiae leptospira pomona recombinant borrelia burgdorferi bordetella bronchiseptica rabies vaccines portfolio rabisin inactivated adjuvanted sustained rabies protection years imrab rabies glycoproteins first year booster consistently high seroconversion rate us othersboehringer ingelheim annual report ch boehringer sohn ag co kg ingelheim rhein comparison balance sheet financial data million eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes exceeding amount plan assets liquid funds current assets total assets equity liabilities december shareholders capital group reserves incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred income total liabilities incl deferred taxes deferred income total equity liabilities summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets depreciation tangible assets p r n ch boehringer sohn ag co kg assets december binger strae intangible assets ingelheim rhein germany tangible assets telephone financial assets fax fixed assets contact inventories corporate division communications public affairs accounts receivable assets incl prepaid expenses matthias reinig deferred taxes exceeding amount plan assets email pressboehringeringelheimcom liquid funds internet wwwboehringeringelheimcom current assets issued total assets ch boehringer sohn ag co kg represented board managing directors hubertus von baumbach chair equity liabilities december carinne brouillon dr michel pairet shareholders capital jean scheftsik de szolnok michael schmelmer group reserves incl balance sheet currency conversion difference concept design layout group profit mpm corporate communication solutions mainz equity attributable parent company wwwmpmde noncontrolling interests photos group equity andreas reeg difference capital consolidation provisions incl deferred taxes printed eberl print gmbh immenstadt liabilities incl deferred income total liabilities incl deferred taxes deferred income copyright total equity liabilities ch boehringer sohn ag co kg rights reserved part annual report may reproduced transmitted form means summary selected financial data electronic photocopy without permission writing net sales ch boehringer sohn ag co kg figures third parties used annual report based data available operating income time financial statements drawn operating income net sales income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales carbon neutral average number employees natureofficecom denkq print production research development expenses rd net sales investments tangible assets co emission certificates support forest conservation forest modification many regions germany depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom